[go: up one dir, main page]

WO2025264020A1 - Use of sphingomonas sp. microorganism for promoting hair growth - Google Patents

Use of sphingomonas sp. microorganism for promoting hair growth

Info

Publication number
WO2025264020A1
WO2025264020A1 PCT/KR2025/008527 KR2025008527W WO2025264020A1 WO 2025264020 A1 WO2025264020 A1 WO 2025264020A1 KR 2025008527 W KR2025008527 W KR 2025008527W WO 2025264020 A1 WO2025264020 A1 WO 2025264020A1
Authority
WO
WIPO (PCT)
Prior art keywords
sphingomonas
olei
hair
growth
culture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/KR2025/008527
Other languages
French (fr)
Korean (ko)
Inventor
최원우
서은영
박민지
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cutisbio Co Ltd
Original Assignee
Cutisbio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cutisbio Co Ltd filed Critical Cutisbio Co Ltd
Publication of WO2025264020A1 publication Critical patent/WO2025264020A1/en
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Definitions

  • the present invention relates to the use of microorganisms of the genus Sphingomonas , particularly Sphingomonas olei , for promoting hair growth or preventing hair loss, and more particularly, to a composition for promoting hair growth or preventing hair loss, comprising a microorganism of the genus Sphingomonas (particularly Sphingomonas olei), or a lysate, culture solution or extract thereof.
  • Hair production in hair follicles undergoes a repetitive cycle of growth, regression, and resting phases.
  • a shortened growth phase or prolonged regression and resting phases can lead to alopecia.
  • Hair loss is caused not only by genetic factors and disease, but also by aging, stress, hormonal changes, irregular lifestyle habits, and excessive use of chemical products.
  • the prevalence of hair loss is increasing not only among middle-aged men but also among young people in their 20s and 30s and among women.
  • the psychological stress caused by hair loss can lower quality of life and significantly disrupt interpersonal relationships and social life. Therefore, it is recognized as a condition requiring active prevention and treatment.
  • the growing number of people with hair loss has led to rapid expansion of the hair loss market.
  • Hair growth is driven by a complex mechanism involving multiple genes, growth factors, and their receptors.
  • the outer root sheath cells of the hair follicle composed of epithelial cells
  • the papilla cells composed of dermal cells
  • the interaction between these two cells leads to a cycle of growth, shedding, and telogen phases.
  • the dermal papilla (DP) of the hair follicle is central to hair growth. It releases growth factors and inhibitory factors into the DP, thereby repeating the cycle of growth, shedding, and telogen phases.
  • Representative genes that promote dermal papilla cell growth include insulin-like growth factor-1 (IGF-1) and vascular endothelial growth factor (VEGF).
  • microorganisms of the genus Sphingomonas particularly Sphingomonas olei, not only promote the expression of hair follicle growth factors but also induce hair growth, thereby completing the present invention.
  • the present invention aims to provide a composition for promoting hair growth or preventing hair loss, comprising a microorganism of the genus Sphingomonas (particularly Sphingomonas olei), or a lysate, culture solution or extract thereof.
  • the present invention aims to provide a cosmetic composition for promoting hair growth or preventing hair loss, comprising a microorganism of the genus Sphingomonas (particularly Sphingomonas olei), or a lysate, culture solution or extract thereof.
  • the present invention provides a pharmaceutical composition for promoting hair growth or preventing hair loss, comprising a microorganism of the genus Sphingomonas (particularly Sphingomonas olei), or a lysate, culture solution or extract thereof.
  • the present invention provides a composition for external application to the skin for promoting hair growth or preventing hair loss, comprising a microorganism of the genus Sphingomonas (particularly Sphingomonas olei), or a lysate, culture solution or extract thereof.
  • the present invention provides a pharmaceutical composition for promoting hair growth or preventing hair loss, comprising a microorganism of the genus Sphingomonas (particularly Sphingomonas olei), or a lysate, culture solution or extract thereof.
  • the present invention provides a health functional food composition for promoting hair growth or preventing hair loss, comprising a microorganism of the genus Sphingomonas (particularly Sphingomonas olei), or a lysate, culture solution or extract thereof.
  • the present invention provides a Sphingomonas olei strain deposited under accession number KACC 81320BP or KACC 81321BP.
  • the present invention seeks to provide a lysate, culture solution, or extract of the above Sphingomonas olei strain.
  • One aspect of the present invention provides a composition for promoting hair growth or preventing hair loss, comprising a microorganism of the genus Sphingomonas (particularly Sphingomonas olei), or a lysate, culture solution or extract thereof.
  • the microorganism of the genus Sphingomonas may be a viable bacterium (living bacterium) or a dead bacterium (dead bacterium). More specifically, the dead bacterium may be a bacterium killed by heat treatment.
  • microorganisms of the genus Sphingomonas include, but are not limited to, the following species: Sphingomonas abaci , Sphingomonas adhaesiva , Sphingomonas aerolata , Sphingomonas aestuarii, Sphingomonas alaskensis , Sphingomonas alpine , Sphingomonas aquatilis, Sphingomonas aromaticivorans , Sphingomonas asaccharolytica , Sphingomonas astaxanthinifaciens Sphingomonas astaxanthinifaciens , Sphingomonas aurantiaca, Sphingomonas azotifigens, Sphingomonas capsulate, Sphingomonas changbaiensis , Sphingomonas chlorophenolica , Sphingomonas chungbukensis , Sphingomonas
  • the microorganism of the genus Sphingomonas may be Sphingomonas olei, and specifically may be a Sphingomonas olei strain deposited under accession number KACC 81169BP, KACC 81320BP or KACC 81321BP.
  • Sphingomonas genus microorganisms can be used singly or in combination of two or more species.
  • lysate refers to a solution or suspension in an aqueous medium of cells of a microorganism, such as a broken microorganism of the genus Sphingomonas.
  • a cell lysate may contain macromolecules such as DNA, RNA, proteins, peptides, carbohydrates, lipids, etc., and/or micromolecules such as amino acids, sugars, fatty acids, etc., or fractions thereof.
  • the lysate may also contain cell debris, which may be smooth or granular in structure.
  • Methods for achieving cell lysis of the above microorganisms can utilize various known methods, and any method capable of achieving cell lysis of the microorganisms can be used.
  • cell opening/disruption can be performed enzymatically, chemically, or physically.
  • Non-limiting examples of enzymes and enzyme mixtures include proteases such as proteinase K, lipases, or glycosidases; non-limiting examples of chemicals include ionophores, detergents such as sodium dodecyl sulfate, acids, or bases; and non-limiting examples of physical means include high pressure such as French pressing, osmotic pressure, and temperatures such as heat or cold.
  • a method using an appropriate combination of enzymes, acids, bases, etc. other than proteolytic enzymes can also be used.
  • culture medium may be used interchangeably with “culture supernatant”, “conditioned culture medium” or “conditioned medium”, and may mean the entire medium containing the microorganism, its metabolites, extra nutrients, etc., obtained by culturing Sphingomonas microorganisms for a certain period of time in a medium that can supply nutrients so that Sphingomonas microorganisms can grow and survive in vitro.
  • the culture medium may mean a culture medium from which the microorganisms have been removed from a cell culture obtained by culturing the microorganisms.
  • the liquid from the culture medium from which the cell bodies have been removed is also called a "supernatant", and may be obtained by allowing the culture medium to stand still for a certain period of time and taking only the liquid in the upper layer excluding the portion that has settled to the lower layer, removing the cell bodies through filtration, or centrifuging the culture medium to remove the sediment at the bottom and taking only the liquid in the upper layer.
  • the "cell bodies” above refers to the microorganisms themselves of the present invention, and includes the microorganisms themselves that have been separated and selected from a skin sample or the like, or the microorganisms that have been separated from the culture medium by culturing the microorganisms.
  • the above-mentioned fungi can be obtained by centrifuging the culture solution and taking the portion that has settled to the lower layer, or by allowing the fungi to settle to the lower layer of the culture solution by gravity and then removing the upper liquid after leaving it still for a certain period of time.
  • the culture of the Sphingomonas microorganism of the present invention can use a medium easily selected by a person skilled in the art according to the purpose among the media used for microbial culture.
  • the culture of the Sphingomonas microorganism can use, for example, TSB (Tryptic soy broth) medium, R2A (Reasoner's 2A) medium, LB (Luria-Bertani) medium, or MH (Mueller Hinton) medium, but is not limited thereto.
  • the culture of the Sphingomonas microorganism of the present invention can be prepared by inoculating the Sphingomonas microorganism into the microbial culture medium and using a microbial culture method known in the art (for example, static culture, etc.).
  • the above culture solution may include the culture solution itself, a concentrate thereof, or a lyophilized product obtained by culturing a microorganism, or a culture supernatant obtained by removing a microorganism from the culture solution, a concentrate thereof, or a lyophilized product thereof.
  • the above culture solution may be obtained by culturing a Sphingomonas genus microorganism in an appropriate medium (e.g., TSB medium) at a temperature of 10°C to 40°C for a certain period of time, for example, 4 to 50 hours.
  • an appropriate medium e.g., TSB medium
  • a person of ordinary skill in the art may appropriately select or modify the culture medium and culture conditions for culturing the Sphingomonas genus microorganism.
  • the culture supernatant of a microorganism can be obtained by a step of removing microorganisms by centrifuging or filtering the microbial culture solution.
  • the concentrate can be obtained by concentrating the microbial culture itself, or the supernatant obtained after filtering the culture using centrifugation or a filter.
  • extract in this specification means an extract from the above-mentioned lysate, culture medium or concentrate thereof, and may include an extract, a diluted or concentrated extract, a dried product obtained by drying the extract, or a controlled or purified product thereof, or a fraction obtained by fractionating the same.
  • the composition is present in an amount of 0.00001 wt% to 80 wt%, for example, 0.00001 wt% to 60 wt%, 0.00001 wt% to 40 wt%, 0.00001 wt% to 30 wt%, 0.00001 wt% to 20 wt%, 0.00001 wt% to 10 wt%, 0.00001 wt% to 5 wt%, 0.05 wt% to 60 wt%, 0.05 wt% to 40 wt%, 0.05 wt% to 30 wt%, 0.05 wt% to 20 wt%, 0.05 wt% to 10 wt%, 0.05 wt% to 5 wt%, 0.1 wt% to 60 wt%, 0.1 wt% to 40 wt%, 0.1 It may include a microorganism, or a lysate, culture medium, or extract thereof, or a mixture of lysates, culture mediums,
  • the term "including as an active ingredient” means that the microorganism, or its lysate, culture medium or extract is added to an extent that it can exhibit the above-mentioned effect, and includes formulating in various forms by adding various components as auxiliary components for drug delivery and stabilization, etc.
  • hair includes hair of the scalp, skin, eyelashes, eyebrows, mustache area and/or beard area of a subject.
  • hair growth promotion means stimulating the production and growth of hair, thereby increasing the proportion of hair in the anagen phase among all hair types. This includes not only stimulating the production of new hair, but also promoting the healthy growth of existing hair. Hair growth promotion includes increasing the length of hair fibers growing in a specific area of the human body, i.e., increasing the length of hair in a given area over a period of time compared to the length of hair not treated with Sphingomonas spp. (particularly Sphingomonas olei ), and/or increasing hair density (i.e., the number of hairs per cm 2 of skin).
  • alopecia refers to the phenomenon of hair falling out from the scalp or a condition in which hair becomes thicker or thinner. Hair loss can be caused by a decrease in the proportion of hair in the growth phase. Hair loss can be caused by exogenous or endogenous factors. Exogenous factors include various external factors, such as ultraviolet rays, while endogenous factors occur over time, including cell death of hair papilla cells due to telomeres and oxidative stress resulting from a decline in cell function.
  • the above hair loss may be one or more selected from, but is not limited to, alopecia areata, androgenetic alopecia, telogen effluvium, traumatic alopecia, hair loss due to trichotillomania, pressure alopecia, anagen alopecia, pityriasis alopecia, alopecia syphlltiac, alopecia seborrhecia, symptomatic alopecia, cicatricial alopecia, and congenital alopecia.
  • hair loss prevention refers to preventing, delaying, or preventing hair loss.
  • prevention may be interchangeable with the term “reduction,” which refers to reducing the amount of hair lost. Therefore, “hair loss prevention” may encompass hair loss improvement, hair loss prevention, hair loss treatment, and the like.
  • a microorganism of the genus Sphingomonas may exhibit hair growth promoting or hair loss preventing activity.
  • a microorganism of the genus Sphingomonas may promote hair length growth, or increase the expression of one or more of factors related to the promotion of hair follicle cell growth, such as insulin-like growth factor 1 (IGF-1), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), platelet-derived growth factor subunit A (PDGFA) and fibroblast growth factor 7 (FGF7).
  • IGF-1 insulin-like growth factor 1
  • VEGF vascular endothelial growth factor
  • HGF hepatocyte growth factor
  • PDGFA platelet-derived growth factor subunit A
  • FGF7 fibroblast growth factor 7
  • the Sphingomonas genus microorganism (particularly Sphingomonas olei), or a lysate, culture or extract thereof, may be used together with other microorganisms effective in promoting hair growth or preventing hair loss.
  • composition for promoting hair growth or preventing hair loss of the present invention can be used for various purposes and uses requiring promotion of hair growth or prevention of hair loss, and specifically, can be used as a cosmetic, a pharmaceutical (e.g., a topical skin preparation), an over-the-counter drug, a food, a health functional food, a detergent, a cleaning agent, a preservative, an antiseptic, a food additive, or a feed additive, but is not limited thereto.
  • a cosmetic e.g., a topical skin preparation
  • an over-the-counter drug e.g., a topical skin preparation
  • a food e.g., a health functional food
  • a detergent e.g., a cleaning agent
  • preservative e.g., an antiseptic, a food additive, or a feed additive, but is not limited thereto.
  • the present invention may be a cosmetic composition for promoting hair growth or preventing hair loss, comprising a microorganism of the genus Sphingomonas (particularly Sphingomonas olei), or a lysate, culture solution or extract thereof.
  • the cosmetic composition can be manufactured in a formulation including a toner (skin lotion), skin, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nourishing lotion, massage cream, nourishing cream, moisture cream, hand cream, hand sanitizer, foundation, essence, nourishing essence, pack, soap, cleansing foam, cleansing lotion, cleansing cream, body lotion, body cleanser, suspension, gel, powder, paste, mask pack, and sheet.
  • a toner skin, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nourishing lotion, massage cream, nourishing cream, moisture cream, hand cream, hand sanitizer, foundation, essence, nourishing essence, pack, soap, cleansing foam, cleansing lotion, cleansing cream, body lotion, body cleanser, suspension, gel, powder, paste, mask pack, and sheet.
  • the composition in such a formulation can be manufactured according to a method conventional in the art.
  • the blending amount of additional ingredients such as the moisturizer can be easily selected by a person skilled in the art
  • the above cosmetic composition may further include functional additives and components included in general cosmetic compositions, and may further include purified water, thickeners, preservatives, stabilizers, solubilizers, surfactants, carriers, fragrances, or combinations thereof that are commonly used.
  • the functional additives may include components selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, high molecular peptides, high molecular polysaccharides, sphingolipids, and seaweed extracts.
  • the carriers may include, for example, alcohols, oils, surfactants, fatty acids, silicone oils, humectants, moisturizers, viscosity modifiers, emulsifiers, stabilizers, ultraviolet scatterers, ultraviolet absorbers, colorants, fragrances, and the like.
  • Compounds/compositions that can be used as the above alcohols, oils, surfactants, fatty acids, silicone oils, humectants, moisturizers, viscosity modifiers, emulsifiers, stabilizers, ultraviolet scatterers, ultraviolet absorbers, colorants, fragrances, etc. are already known in the art, so a person skilled in the art can select and use the appropriate corresponding substances/compositions.
  • the cosmetic composition may further contain, as necessary, ingredients such as sunscreens, antioxidants (butylated hydroxyanisole, propyl gallate, ellisorbic acid, tocopheryl acetate, butylated hydroxytoluene, etc.), preservatives (methylparaben, butylparaben, propylparaben, phenoxyethanol, imidazolidinyl urea, chlorphenesin, etc.), colorants, pH adjusters (triethanolamine, citric acid, citric acid, sodium citrate, malic acid, sodium malate, formaldehyde, sodium formaldehyde, succinic acid, sodium succinate, sodium hydroxide, sodium hydrogen phosphate, etc.), moisturizers (glycerin, sorbitol, propylene glycol, butylene glycol, hexylene glycol, diglycerin, betaine, glycereth-26, methylgluceth-20, etc.), and lubricants.
  • sunscreens antioxidants (
  • appropriate ingredients can be selected and blended according to the cosmetic formulation or intended use. Since the blending ingredients and method can be achieved using conventional techniques, a detailed description thereof is omitted herein.
  • a pharmaceutical composition for promoting hair growth or preventing hair loss comprising a microorganism of the genus Sphingomonas (particularly Sphingomonas olei), or a lysate, culture solution or extract thereof.
  • composition may refer to a molecule or compound that, when administered to a subject, imparts several beneficial effects.
  • beneficial effects may include enabling diagnostic determination; improving a disease, symptom, disorder, or condition; reducing or preventing the onset of a disease, symptom, disorder, or condition; and generally combating a disease, symptom, disorder, or condition.
  • prevention refers to a method of partially or completely delaying or preventing the onset or recurrence of a disease, disorder, or its associated symptoms, preventing the acquisition or reacquisition of a disease or disorder, or reducing the risk of acquiring a disease or disorder.
  • prevention refers to any action that inhibits or delays the onset of skin damage or symptoms by administering a composition according to the present invention.
  • treatment includes inhibition, alleviation or elimination of the development of a disease.
  • improvement herein may mean any action that at least reduces the severity of a symptom, for example, a parameter related to alleviation or treatment of a condition.
  • a microorganism of the genus Sphingomonas may be included in a pharmaceutical composition having hair growth promotion or hair loss prevention activity, or may be used as an adjuvant of an active ingredient having a medicinal use.
  • the pharmaceutical composition may be prepared according to a method well known to those skilled in the art.
  • the pharmaceutical composition described above can be administered orally or parenterally, depending on the intended method, and can be used in the form of a general pharmaceutical formulation.
  • Parenteral administration can refer to administration via routes other than oral administration, such as rectal, intravenous, peritoneal, intramuscular, arterial, transdermal, nasal, inhalational, ocular, and subcutaneous.
  • the pharmaceutical composition can be applied to the scalp.
  • the pharmaceutical composition of the present invention when used as a medicine, it may additionally contain one or more active ingredients exhibiting the same or similar function.
  • the above pharmaceutical composition may be further manufactured by including at least one pharmaceutically acceptable carrier.
  • Pharmaceutically acceptable carriers include saline solution, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, and mixtures of at least one of these components. If necessary, other conventional additives such as antioxidants, buffers, and bacteriostatic agents may be added.
  • diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate the composition into injectable formulations such as aqueous solutions, suspensions, and emulsions, pills, capsules, granules, or tablets.
  • the composition may be preferably formulated according to each disease or component using an appropriate method in the art.
  • diluents or excipients such as fillers, bulking agents, binders, wetting agents, disintegrating agents, and surfactants that are commonly used.
  • Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories.
  • Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate.
  • Suppository bases may include Witepsol, macrogol, Tween 61, cacao butter, liurin butter, and glycerogelatin.
  • the pharmaceutical composition may contain carbohydrates such as glucose, sucrose or dextran, antioxidants such as ascorbic acid or glutathione, chelating agents, low-molecular-weight proteins or other stabilizers to increase stability or absorbability.
  • carbohydrates such as glucose, sucrose or dextran
  • antioxidants such as ascorbic acid or glutathione
  • chelating agents such as ascorbic acid or glutathione
  • low-molecular-weight proteins or other stabilizers to increase stability or absorbability.
  • the pharmaceutical composition may be a skin external application composition for promoting hair growth or preventing hair loss.
  • the above-mentioned skin external preparation may be a cream, gel, ointment, skin emulsifier, skin suspension, transdermal patch, lotion, or a combination thereof.
  • the above-mentioned skin external preparation may be appropriately mixed with ingredients commonly used in skin external preparations such as cosmetics or medicines, such as aqueous ingredients, oily ingredients, powder ingredients, alcohols, moisturizers, thickeners, UV absorbers, whitening agents, preservatives, antioxidants, surfactants, fragrances, colorants, various skin nutrients, or a combination thereof, as needed.
  • the above skin external preparation may also appropriately contain metal sequestrants such as sodium edetate, trisodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate, and gluconic acid; caffeine, tannin, bellapamil, licorice extract, glabridin, various herbal medicines, tocopherol acetate, glycyrrhizic acid, tranexamic acid and derivatives or salts thereof; and sugars such as vitamin C, magnesium ascorbic acid phosphate, ascorbic acid glucoside, arbutin, kojic acid, glucose, fructose, and trehalose.
  • metal sequestrants such as sodium edetate, trisodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate, and gluconic acid
  • caffeine tannin, bellapamil, licorice extract, glabridin, various herbal medicines, tocopherol acetate, glycyrrhizic acid, tranexamic acid
  • the skin external application composition according to the present invention may contain 0.00001 wt% to 80 wt% of a microorganism, its lysate, culture solution or extract based on the total weight of the composition.
  • the above skin includes all skin areas of the body, including the face, hands, arms, legs, feet, chest, stomach, back, buttocks, and scalp.
  • Another aspect of the present invention provides a method for preventing, improving, or treating a condition of a subject, comprising administering or applying to the subject a microorganism of the genus Sphingomonas (particularly Sphingomonas olei), or a lysate, culture, or extract thereof.
  • the condition of the above object may be a condition requiring promotion of hair growth or prevention of hair loss.
  • administering means to placement of a composition according to one embodiment into a subject by a method or route that results in at least partial localization of the composition to a desired site according to one embodiment.
  • Administration can be administered by any method known in the art. Administration can be administered directly to the subject by any means, including intravenous, intramuscular, oral, transdermal, mucosal, nasal, intratracheal, or subcutaneous administration. Administration can be systemic or local.
  • the subject may be a mammal, such as a human, cow, horse, pig, dog, sheep, goat, or cat.
  • the subject may be an individual in need of hair growth promotion or hair loss prevention.
  • the above administration is 0.00001 mg to 1,000 mg of the composition according to one specific example per subject per day, for example, 0.00001 mg to 500 mg, 0.00001 mg to 100 mg, 0.00001 mg to 50 mg, 0.00001 mg to 25 mg, 1 mg to 1,000 mg, 1 mg to 500 mg, 1 mg to 100 mg, 1 mg to 50 mg, 1 mg to 25 mg, 5 mg to 1,000 mg, 5 mg to 500 mg, 5 mg to 100 mg, 5 mg to 50 mg, 5 mg to 25 mg, 10 mg to 1,000 mg, 10 mg to 500 mg, 10 mg to 100 mg, 10 mg to 50 mg, Or it may be administered 10 mg to 25 mg.
  • the dosage may be prescribed in various ways depending on factors such as the formulation method, administration method, patient's age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and response sensitivity, and a person of ordinary skill in the art can appropriately adjust the dosage by considering these factors.
  • the frequency of administration may be once a day or twice or more within the range of clinically acceptable side effects, and the administration site may be administered in one or more sites, and the total number of administration days may be from 1 to 30 days per treatment, daily or at intervals of 2 to 5 days. If necessary, the same treatment may be repeated after an appropriate period.
  • the same dosage as for humans per kg may be administered, or the above dosage may be converted into an amount based on the volume ratio (e.g., average value) of the organs (heart, etc.) of the target animal and humans.
  • the present invention provides a composition comprising a microorganism of the genus Sphingomonas (particularly Sphingomonas olei), or a lysate, culture solution or extract thereof, for use in promoting hair growth or preventing hair loss.
  • Another aspect of the present invention provides a method for promoting hair growth or preventing hair loss, comprising the step of treating an organism with a microorganism of the genus Sphingomonas (particularly Sphingomonas olei), or a lysate, culture solution or extract thereof.
  • a method for treating an organism with a microorganism of the genus Sphingomonas (particularly Sphingomonas olei) or a lysate, culture medium or extract thereof can be appropriately used according to a conventional method well known to those skilled in the art in various fields requiring promotion of hair growth or prevention of hair loss.
  • the amount of the microorganism of the genus Sphingomonas (particularly Sphingomonas olei) or a lysate, culture medium or extract thereof can be appropriately determined depending on the intended use.
  • a composition for promoting hair growth or preventing hair loss comprising a microorganism of the genus Sphingomonas (particularly Sphingomonas olei), or a lysate, culture solution or extract thereof, may be a quasi-drug composition.
  • the term "quasi-drug” means a product that is used for the purpose of diagnosing, treating, improving, alleviating, managing or preventing diseases of humans or animals, and has a milder effect than a drug.
  • a quasi-drug is a product excluding products used for the purpose of drugs, and includes fiber and rubber products used for the treatment or prevention of diseases of humans or animals, products that have a mild or no direct effect on the human body, are not instruments or machines or similar thereto, and sterilizers and insecticides for preventing infectious diseases.
  • the type or formulation of the pharmaceutical composition of the present invention is not particularly limited, but may be a bandage, gauze, cotton, adhesive bandage, disinfectant, shower foam, gargle, wet tissue, detergent soap, hand wash, humidifier filler, mask, or filter filler.
  • the composition of the present invention When the composition of the present invention is included in an over-the-counter drug for the purpose of promoting hair growth or preventing hair loss, the composition may be used as is or in combination with other over-the-counter drug ingredients, and may be used appropriately according to a conventional method.
  • the mixing amount of the active ingredients may be appropriately determined depending on the intended use, and the over-the-counter drug composition according to the present invention may contain 0.01 wt% to 20 wt% of microorganisms, their lysates, cultures, or extracts based on the total weight of the composition.
  • a composition for promoting hair growth or preventing hair loss comprising a microorganism of the genus Sphingomonas (particularly Sphingomonas olei), or a lysate, culture solution or extract thereof, may be a health functional food composition.
  • the above health functional food composition may be used alone or in combination with other foods or food ingredients, and may be used by conventional methods, including using microorganisms of the genus Sphingomonas (particularly Sphingomonas olei) or their lysates, culture solutions, or extracts.
  • the amount of the active ingredients may be appropriately determined depending on the intended use (prevention, health, or therapeutic treatment).
  • the composition of the present specification may be added in an amount of 15 parts by weight or less relative to the raw materials.
  • beverage compositions may contain various flavorings or natural carbohydrates as additional ingredients, just like conventional beverages.
  • the above natural carbohydrates include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol.
  • a natural sweetener such as thaumatin and stevia extract, or a synthetic sweetener such as saccharin or aspartame can be used.
  • the above health food composition may also contain a nutrient, a vitamin, an electrolyte, a flavoring agent, a coloring agent, a pectic acid and its salts, an alginic acid and its salts, an organic acid, a protective colloid thickener, a pH adjusting agent, a stabilizer, a preservative, glycerin, alcohol, a carbonating agent used in carbonated beverages, or a combination thereof.
  • the above health functional food composition may also contain fruit pulp for the production of natural fruit juice, fruit juice beverage, or vegetable beverage, or a combination thereof.
  • Another aspect of the present invention provides a Sphingomonas olei strain deposited under accession number KACC 81320BP or KACC 81321BP.
  • the Sphingomonas olei strain deposited with accession number KACC 81320BP may include 16S rRNA of sequence number 2
  • the Sphingomonas olei strain deposited with accession number KACC 81321BP may include 16S rRNA of sequence number 3.
  • the above Sphingomonas olei strain can promote hair length growth or increase the expression of one or more growth-promoting factors of hair follicle cells, such as IGF-1, VEGF, HGF, PDGFA, and FGF7. Therefore, the above Sphingomonas olei strain can be used for hair growth promotion or hair loss prevention.
  • Another aspect of the present invention provides a lysate, culture solution, or extract of the Sphingomonas olei strain.
  • the lysate, culture medium, or extract of the above Sphingomonas olei strain can promote hair length growth or increase the expression of one or more growth-promoting factors of hair follicle cells, such as IGF-1, VEGF, HGF, PDGFA, and FGF7. Therefore, the lysate, culture medium, or extract of the above Sphingomonas olei strain can be used for promoting hair growth or preventing hair loss.
  • a composition comprising a microorganism of the genus Sphingomonas (particularly Sphingomonas olei) or a lysate, culture solution or extract thereof according to one aspect of the present invention can be usefully used for promoting hair growth or preventing hair loss by increasing the growth rate of hair length and increasing the expression of growth-promoting factors of hair follicle cells.
  • Figure 1 shows the hair growth effect of Sphingomonas olei culture using human hair follicle organ culture. It is a graph showing the results of measuring the length of hair grown on the 2nd and 4th days after treating human hair follicle tissue with 4% (v/v) of Sphingomonas olei culture.
  • Figure 2 is a photograph showing the hair growth effect of Sphingomonas olei culture using human hair follicle organ culture. It is a photograph of hair on the 6th day after treating human hair follicle tissue with 4% (v/v) of Sphingomonas olei culture.
  • Figure 3 shows the results of confirming cytotoxicity after treating human breast papilla cells with 0.2%, 0.4%, or 1% (v/v) of Sphingomonas olei culture solution.
  • Figure 4 is a graph showing the results of real-time PCR analysis of the expression levels of hair follicle growth factors IGF-1, VEGF, HGF, PDGFA, and FGF7 48 hours after treatment of 0.4% or 0.8% (v/v) of Sphingomonas olei culture solution in human hair papilla cells isolated from the human body.
  • Figure 5 is a graph showing the results of real-time PCR analysis of the relative expression level of hair follicle growth factor IGF-1 mRNA 24 hours after treatment with 1% culture of Sphingomonas olei strain in human hair papilla cells (CON, negative control group (sterile distilled water); So-1, Sphingomonas olei KACC 81169BP; So-2, Sphingomonas olei KACC 81320BP; So-3, Sphingomonas olei KACC 81321BP).
  • Sphingomonas olei KACC 81169BP strain was cultured in TSB medium at 34°C for 24 hours with stirring, and the strain culture was collected at the final point of the division phase (Log phase) of the growth curve. The culture was centrifuged at 6,000 rpm for 30 minutes and sterilized by filtration using a 0.2 ⁇ m filter. Evaluation and activity analysis were performed no longer than 1 day after preparation.
  • Example 1 To determine whether the Sphingomonas olei culture prepared in Example 1 promotes hair growth, human hair follicle organs were cultured and hair growth was evaluated.
  • hair follicles were isolated one by one from human hair follicle tissue, and the subcutaneous fat layer was removed as much as possible to prevent contamination with fibroblasts, which are dermal cells of the skin.
  • 350 ⁇ L of Williams's E Medium containing 2 mM L-glutamine, 10 ⁇ g/mL insulin, 10 ng/mL hydrocortisone, 100 ⁇ g/mL streptomycin, and 100 U/mL penicillin was added to each well of a 48-well plate, and one hair follicle was placed per well and cultured in a 37°C, 5% CO 2 cell incubator. Eight hair follicles were used per experimental group, and the culture medium was replaced every two days with the Sphingomonas olei culture solution.
  • the Sphingomonas olei culture solution was treated at a concentration of 4%, and sterile distilled water was used for the negative control group. Length measurements were taken from each hair follicle before adding the Sphingomonas olei culture medium, using this as a reference point. Hair length was measured every two days, and the reference point length was used as the hair growth length. The results are shown in Figures 1 and 2.
  • Figure 1 is a graph showing the results of measuring the length grown on the 2nd and 4th days after treating human hair follicle tissue with a 4% (v/v) Sphingomonas olei culture solution.
  • Figure 1 shows that, compared to the negative control group, the length of hair follicles in the Sphingomonas olei culture treatment group grew approximately 20% more on days 2 and 4. Therefore, it was confirmed that the Sphingomonas olei culture was effective in early hair follicle growth.
  • Figure 2 is a photograph of hair taken on the 6th day after treating human hair follicle tissue with a 4% (v/v) Sphingomonas olei culture solution.
  • a cytotoxicity test was performed to determine whether the Sphingomonas olei culture solution prepared in Example 1 could exhibit toxicity to cells.
  • human hair follicle dermal papilla (DP) cells were seeded in 96-well plates at 2 ⁇ 10 4 cells/well and cultured in DMEM medium (Dubelcco's modified eagle medium) containing 0.25% fetal bovine serum (FBS), 100 ⁇ g/mL streptomycin, and 100 U/mL penicillin at 37°C in a 5% CO 2 incubator. After 24 h of culture under the same conditions, Sphingomonas olei culture was treated at concentrations of 0.2%, 0.4%, and 1% (v/v) and cultured for an additional 48 h.
  • DMEM medium Dubelcco's modified eagle medium
  • FBS fetal bovine serum
  • streptomycin 100 ⁇ g/mL streptomycin
  • penicillin 100 U/mL penicillin
  • Figure 3 is a graph showing the results of evaluating the viability of human breast papilla cells according to treatment with the Sphingomonas olei culture solution prepared in Example 1 using the WST-1 assay.
  • Example 4 Analysis of hair follicle growth factor expression using Sphingomonas olei culture solution.
  • IGF-1 insulin-like growth factor 1
  • VEGF vascular endothelial growth factor
  • HGF hepatocyte growth factor
  • PDGFA platelet-derived growth factor subunit A
  • FGF7 fibroblast growth factor 7
  • human dermal papilla cells were cultured in DMEM medium containing 0.25% bovine serum, 100 ⁇ g/mL streptomycin, and 100 U/mL penicillin in a 6-well plate at 37°C in a 5% CO2 incubator. When the cells reached 80–90% of the plate area, the medium was replaced and cultured under the same conditions for 24 h. Then, Sphingomonas olei culture was treated at concentrations of 0.4% and 0.8% (v/v) and cultured for an additional 48 h. Sterile distilled water was used as a negative control. RNA was extracted using Trizol, and cDNA was synthesized using 2 ⁇ g of RNA each.
  • Figure 4 is a graph showing the results of real-time PCR analysis of the relative expression levels of mRNA of hair follicle growth factors IGF-1, VEGF, HGF, PDGFA, and FGF7 48 hours after treatment of 0.4% or 0.8% (v/v) of Sphingomonas olei culture solution in human hair papilla cells isolated from the human body.
  • the expression of IGF-1, VEGF, HGF, PDGFA, and FGF7 increased compared to the negative control group when treated with 0.4% or 0.8% Sphingomonas olei culture solution, and in particular, the expression of IGF-1, VEGF, HGF, PDGFA, and FGF7 significantly increased compared to the control group when treated with 0.8% Sphingomonas olei culture solution. Therefore, it can be seen that Sphingomonas olei culture solution promotes the expression of hair follicle growth factors.
  • Example 5 Analysis of hair follicle growth factor expression by various Sphingomonas olei strain cultures.
  • IGF-1 a representative growth factor that is most strongly expressed in the growth phase of dermal papilla cells and induces cell proliferation.
  • Sphingomonas olei KACC 81169BP strain used in Examples 1 to 4 two strains isolated from the skin of a healthy Korean person and identified as Sphingomonas olei through analysis of 16S rRNA sequences were used.
  • the Sphingomonas olei KACC 81169BP, KACC 81320BP, and KACC 81321BP strains have the 16S rRNA sequences of SEQ ID NOs: 1 to 3, respectively.
  • human dermal papilla cells were cultured in a 6-well plate in DMEM medium containing 10% FBS (Fatal calf serum), 100 ⁇ g/mL streptomycin, and 100 U/mL penicillin using the same method as in Example 1 in a 5% CO2 incubator at 37°C.
  • FBS Fetal calf serum
  • streptomycin 100 ⁇ g/mL
  • penicillin 100 U/mL
  • the medium was replaced with 0.25% FBS-DMEM and cultured under the same conditions for 24 hours, then treated with Sphingomonas olei culture medium at a concentration of 1% (v/v) and cultured for an additional 24 hours.
  • Sterile distilled water was used as a negative control.
  • RNA was extracted using Trizol, and cDNA was synthesized using 1 ⁇ g of total RNA each. Real-time PCR was performed on the IGF-1 gene using the synthesized cDNA as a template. At this time, the expression level of the gene was finally analyzed
  • Figure 5 is a graph showing the results of real-time PCR analysis of the relative expression level of hair follicle growth factor IGF-1 mRNA 24 hours after treatment with 1% culture of Sphingomonas olei strain in human hair papilla cells (CON, negative control group (sterile distilled water); So-1, Sphingomonas olei KACC 81169BP; So-2, Sphingomonas olei KACC 81320BP; So-3, Sphingomonas olei KACC 81321BP).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Birds (AREA)
  • Biochemistry (AREA)
  • Cosmetics (AREA)

Abstract

The present invention relates to a use of a Sphingomonas sp. microorganisms, particularly Sphingomonas olei, for promoting hair growth or preventing hair loss. A composition comprising a Sphingomonas sp. microorganism (particularly Sphingomonas olei) or a lysate, culture medium, or extract thereof enhances the growth rate of hair length and increases the expression of growth promotion-related factors of hair follicle cells, and thus is useful for promoting hair growth or preventing hair loss.

Description

스핑고모나스 속 미생물의 모발 성장 촉진 용도Use of Sphingomonas spp. for hair growth promotion

본 발명은 스핑고모나스 속(Sphingomonas sp.) 미생물, 특히 스핑고모나스 올레이(Sphingomonas olei)의 모발 성장 촉진 또는 탈모 예방 용도에 관한 것으로, 구체적으로 스핑고모나스 속 미생물(특히 스핑고모나스 올레이), 또는 이의 용해물, 배양액 또는 추출물을 포함하는, 모발 성장 촉진 또는 탈모 예방용 조성물에 관한 것이다.The present invention relates to the use of microorganisms of the genus Sphingomonas , particularly Sphingomonas olei , for promoting hair growth or preventing hair loss, and more particularly, to a composition for promoting hair growth or preventing hair loss, comprising a microorganism of the genus Sphingomonas (particularly Sphingomonas olei), or a lysate, culture solution or extract thereof.

모낭에서 모발 생성은 성장기, 퇴행기 및 휴지기의 반복되는 주기를 가지며 성장기가 단축되거나 퇴행기와 휴지기가 길어짐에 의해 탈모증이 발생한다. 탈모는 유전적 요인과 질병에 의해서 뿐만 아니라, 노화, 스트레스, 호르몬 변화, 불규칙한 생활습관과 과도한 화학제품 사용 등의 여러가지 원인에 의해 발생되어 중년 남성뿐만 아니라 20~30대 젊은 층과 여성 탈모도 증가하는 추세다. 외모를 중시하는 현대에는 탈모로 인한 정신적 스트레스가 삶의 질을 저하시키고 대인관계나 사회 생활에 많은 지장을 초래하여 적극적으로 예방과 치료하는 질환으로 인식되고 있다. 탈모 인구의 증가로 탈모 시장은 급팽창하고 있다. 하지만 현재까지 효과가 우수하면서 장기적 사용에 따른 부작용이 적은 탈모제는 없는 실정이다. 따라서, 모낭 성장을 촉진하는 물질의 발굴이 필요하다.Hair production in hair follicles undergoes a repetitive cycle of growth, regression, and resting phases. A shortened growth phase or prolonged regression and resting phases can lead to alopecia. Hair loss is caused not only by genetic factors and disease, but also by aging, stress, hormonal changes, irregular lifestyle habits, and excessive use of chemical products. The prevalence of hair loss is increasing not only among middle-aged men but also among young people in their 20s and 30s and among women. In today's world, where appearance is paramount, the psychological stress caused by hair loss can lower quality of life and significantly disrupt interpersonal relationships and social life. Therefore, it is recognized as a condition requiring active prevention and treatment. The growing number of people with hair loss has led to rapid expansion of the hair loss market. However, currently, there are no hair loss treatments that are both highly effective and have minimal side effects with long-term use. Therefore, the discovery of substances that promote hair follicle growth is crucial.

모발의 성장은 여러 유전자와 성장인자 및 그 수용체가 관여하는 복잡한 작용 기전에 의해 일어난다. 특히, 상피세포로 이루어진 모낭의 외모근초 세포(outer root sheath cell)와 진피세포로 구성된 유두 세포가 모발의 형성 및 성장에 중추적인 요소로 작용한다. 두 세포의 상호 작용에 따라 성장기, 탈락기, 및 휴지기의 사이클을 순환한다. 모발 성장의 핵심은 모낭의 진피유두(dermal papilla: DP)로서, 모낭 성장 인자와 저해 인자를 모낭 외모근초 세포로 방출해서 성장과 탈락, 휴지기의 사이클을 반복하게 한다. 진피유두 세포의 성장을 촉진하는 대표적인 유전자로 IGF-1(insulin-like growth factor-1)과 VEGF(vascular endothelial growth factor)가 알려져 있다. 이들 성장인자는 모낭의 성장기에서 가장 강하게 발현되며, 진피유두 세포의 증식을 유도하고 성장기를 유지시킴으로써 모발이 정상적으로 유지될 수 있도록 돕는 것으로 알려져 있다. 따라서, 진피 유두세포에서 모낭 성장 인자들의 발현을 증가시키는 물질을 찾고자 하는 시도가 발모제 개발의 기본 전제 조건이라고 할 수 있다. Hair growth is driven by a complex mechanism involving multiple genes, growth factors, and their receptors. In particular, the outer root sheath cells of the hair follicle, composed of epithelial cells, and the papilla cells, composed of dermal cells, play a pivotal role in hair formation and growth. The interaction between these two cells leads to a cycle of growth, shedding, and telogen phases. The dermal papilla (DP) of the hair follicle is central to hair growth. It releases growth factors and inhibitory factors into the DP, thereby repeating the cycle of growth, shedding, and telogen phases. Representative genes that promote dermal papilla cell growth include insulin-like growth factor-1 (IGF-1) and vascular endothelial growth factor (VEGF). These growth factors are most strongly expressed during the anagen phase of the hair follicle, inducing the proliferation of dermal papilla cells and maintaining the anagen phase, thereby helping to maintain hair growth. Therefore, it can be said that the attempt to find a substance that increases the expression of hair follicle growth factors in dermal papilla cells is a basic prerequisite for the development of hair growth agents.

본 발명에서는 스핑고모나스 속 미생물, 특히 스핑고모나스 올레이가 모낭 성장 인자들의 발현을 촉진할 뿐만 아니라 모발 성장을 유도함을 확인하고 본 발명을 완성하게 되었다.In the present invention, it was confirmed that microorganisms of the genus Sphingomonas, particularly Sphingomonas olei, not only promote the expression of hair follicle growth factors but also induce hair growth, thereby completing the present invention.

이에, 본 발명은 스핑고모나스 속 미생물(특히 스핑고모나스 올레이), 또는 이의 용해물, 배양액 또는 추출물을 포함하는, 모발 성장 촉진 또는 탈모 예방용 조성물을 제공하고자 한다.Accordingly, the present invention aims to provide a composition for promoting hair growth or preventing hair loss, comprising a microorganism of the genus Sphingomonas (particularly Sphingomonas olei), or a lysate, culture solution or extract thereof.

구체적으로, 본 발명은 스핑고모나스 속 미생물(특히 스핑고모나스 올레이), 또는 이의 용해물, 배양액 또는 추출물을 포함하는, 모발 성장 촉진 또는 탈모 예방용 화장료 조성물을 제공하고자 한다.Specifically, the present invention aims to provide a cosmetic composition for promoting hair growth or preventing hair loss, comprising a microorganism of the genus Sphingomonas (particularly Sphingomonas olei), or a lysate, culture solution or extract thereof.

본 발명은 스핑고모나스 속 미생물(특히 스핑고모나스 올레이), 또는 이의 용해물, 배양액 또는 추출물을 포함하는, 모발 성장 촉진 또는 탈모 예방용 약학 조성물을 제공하고자 한다.The present invention provides a pharmaceutical composition for promoting hair growth or preventing hair loss, comprising a microorganism of the genus Sphingomonas (particularly Sphingomonas olei), or a lysate, culture solution or extract thereof.

본 발명은 스핑고모나스 속 미생물(특히 스핑고모나스 올레이), 또는 이의 용해물, 배양액 또는 추출물을 포함하는, 모발 성장 촉진 또는 탈모 예방용 피부 외용제 조성물을 제공하고자 한다.The present invention provides a composition for external application to the skin for promoting hair growth or preventing hair loss, comprising a microorganism of the genus Sphingomonas (particularly Sphingomonas olei), or a lysate, culture solution or extract thereof.

본 발명은 스핑고모나스 속 미생물(특히 스핑고모나스 올레이), 또는 이의 용해물, 배양액 또는 추출물을 포함하는, 모발 성장 촉진 또는 탈모 예방용 의약외품 조성물을 제공하고자 한다.The present invention provides a pharmaceutical composition for promoting hair growth or preventing hair loss, comprising a microorganism of the genus Sphingomonas (particularly Sphingomonas olei), or a lysate, culture solution or extract thereof.

본 발명은 스핑고모나스 속 미생물(특히 스핑고모나스 올레이), 또는 이의 용해물, 배양액 또는 추출물을 포함하는, 모발 성장 촉진 또는 탈모 예방용 건강기능식품 조성물을 제공하고자 한다.The present invention provides a health functional food composition for promoting hair growth or preventing hair loss, comprising a microorganism of the genus Sphingomonas (particularly Sphingomonas olei), or a lysate, culture solution or extract thereof.

또한, 본 발명은 수탁번호 KACC 81320BP 또는 KACC 81321BP로 기탁된 스핑고모나스 올레이 균주를 제공하고자 한다. In addition, the present invention provides a Sphingomonas olei strain deposited under accession number KACC 81320BP or KACC 81321BP.

본 발명은 상기 스핑고모나스 올레이 균주의 용해물, 배양액, 또는 추출물을 제공하고자 한다.The present invention seeks to provide a lysate, culture solution, or extract of the above Sphingomonas olei strain.

본 발명의 일 양상은 스핑고모나스 속 미생물(특히 스핑고모나스 올레이), 또는 이의 용해물, 배양액 또는 추출물을 포함하는, 모발 성장 촉진 또는 탈모 예방용 조성물을 제공한다.One aspect of the present invention provides a composition for promoting hair growth or preventing hair loss, comprising a microorganism of the genus Sphingomonas (particularly Sphingomonas olei), or a lysate, culture solution or extract thereof.

본 발명에서, 스핑고모나스 속 미생물(특히 스핑고모나스 올레이)은 생균(살아있는 균)이거나 사균(죽어있는 균)일 수 있다. 더욱 상세하게는 상기 사균은 열처리에 의한 사균일 수 있다. In the present invention, the microorganism of the genus Sphingomonas (particularly Sphingomonas olei) may be a viable bacterium (living bacterium) or a dead bacterium (dead bacterium). More specifically, the dead bacterium may be a bacterium killed by heat treatment.

본 발명에서 스핑고모나스 속 미생물은 예를 들어 하기 종들을 포함하나, 이에 한정되지 않는다: 스핑고모나스 아바시(Sphingomonas abaci), 스핑고모나스 애드해시바(Sphingomonas adhaesiva), 스핑고모나스 애롤라타(Sphingomonas aerolata), 스핑고모나스 애스투아리이(Sphingomonas aestuarii), 스핑고모나스 알라스켄시스(Sphingomonas alaskensis), 스핑고모나스 알파인(Sphingomonas alpine), 스핑고모나스 아쿠아틸리스(Sphingomonas aquatilis), 스핑고모나스 아로마티시보란스(Sphingomonas aromaticivorans), 스핑고모나스 아사카로라이티카(Sphingomonas asaccharolytica), 스핑고모나스 아스탁산티니파시엔스(Sphingomonas astaxanthinifaciens), 스핑고모나스 아우란티아카(Sphingomonas aurantiaca), 스핑고모나스 아조티피겐스(Sphingomonas azotifigens), 스핑고모나스 캡슐레이트(Sphingomonas capsulate), 스핑고모나스 창바이엔시스(Sphingomonas changbaiensis), 스핑고모나스 클로로페놀리카(Sphingomonas chlorophenolica), 스핑고모나스 충부켄시스(Sphingomonas chungbukensis), 스핑고모나스 클로아캐(Sphingomonas cloacae), 스핑고모나스 사이나래(Sphingomonas cynarae), 스핑고모나스 데시카빌리스(Sphingomonas desiccabilis), 스핑고모나스 독도넨시스(Sphingomonas dokdonensis), 스핑고모나스 에키노이데스(Sphingomonas echinoides), 스핑고모나스 엔도파이티카(Sphingomonas endophytica), 스핑고모나스 패니(Sphingomonas faeni), 스핑고모나스 페니카(Sphingomonas fennica), 스핑고모나스 포르모센시스(Sphingomonas formosensis), 스핑고모나스 긴센기솔리(Sphingomonas ginsengisoli), 스핑고모나스 긴세노시디무탄스(Sphingomonas ginsenosidimutans), 스핑고모나스 글라시알리스(Sphingomonas glacialis), 스핑고모나스 할로아로마티카만스(Sphingomonas haloaromaticamans), 스핑고모나스 한쿠켄시스(Sphingomonas hankookensis), 스핑고모나스 헤르비시도보란스(Sphingomonas herbicidovorans), 스핑고모나스 히스티디닐라이티카(Sphingomonas histidinilytica), 스핑고모나스 인디카(Sphingomonas indica), 스핑고모나스 인슐래(Sphingomonas insulae), 스핑고모나스 자포니카(Sphingomonas japonica), 스핑고모나스 자스프시(Sphingomonas jaspsi), 스핑고모나스 제주엔시스(Sphingomonas jejuensis), 스핑고모나스 진주엔시스(Sphingomonas jinjuensis), 스핑고모나스 카이스텐시스(Sphingomonas kaistensis), 스핑고모나스 코레엔시스(Sphingomonas koreensis), 스핑고모나스 라테라리애(Sphingomonas laterariae), 스핑고모나스 레이다이(Sphingomonas leidyi), 스핑고모나스 마크로골리타비다(Sphingomonas macrogolitabida), 스핑고모나스 마크로골타비두스(Sphingomonas macrogoltabidus), 스핑고모나스 말리(Sphingomonas mali), 스핑고모나스 멜로니스(Sphingomonas melonis), 스핑고모나스 몰루스코룸(Sphingomonas molluscorum), 스핑고모나스 무코시스시마(Sphingomonas mucosissima), 스핑고모나스 나타토리아(Sphingomonas natatoria), 스핑고모나스 올레이(Sphingomonas olei), 스핑고모나스 올리고페놀리카(Sphingomonas oligophenolica), 스핑고모나스 오리지테래(Sphingomonas oryziterrae), 스핑고모나스 판니(Sphingomonas panni), 스핑고모나스 파라파우시모빌리스(Sphingomonas parapaucimobilis), 스핑고모나스 파우시모빌리스(Sphingomonas paucimobilis), 스핑고모나스 파일로스패래(Sphingomonas phyllosphaerae), 스핑고모나스 피투이토사(Sphingomonas pituitosa), 스핑고모나스 폴리아로마티시보란스(Sphingomonas polyaromaticivorans), 스핑고모나스 프루니(Sphingomonas pruni), 스핑고모나스 슈도산귀니스(Sphingomonas pseudosanguinis), 스핑고모나스 로사(Sphingomonas rosa), 스핑고모나스 로세이플라바(Sphingomonas roseiflava), 스핑고모나스 루브라(Sphingomonas rubra), 스핑고모나스 산귀니스(Sphingomonas sanguinis), 스핑고모나스 산자니게넨스(Sphingomonas sanxanigenens), 스핑고모나스 세디미니콜라(Sphingomonas sediminicola), 스핑고모나스 솔리(Sphingomonas soli), 스핑고모나스 스타른베르겐시스(Sphingomonas starnbergensis), 스핑고모나스 스타이기아(Sphingomonas stygia), 스핑고모나스 수바르크티카(Sphingomonas subarctica), 스핑고모나스 수베리파시엔스(Sphingomonas suberifaciens), 스핑고모나스 수브테라네안(Sphingomonas subterranean), 스핑고모나스 태조넨시스(Sphingomonas taejonensis), 스핑고모나스 테래(Sphingomonas terrae), 스핑고모나스 트루에페리(Sphingomonas trueperi), 스핑고모나스 우르신콜라(Sphingomonas ursincola), 스핑고모나스 위티키이(Sphingomonas wittichii), 스핑고모나스 제노파가(Sphingomonas xenophaga), 스핑고모나스 진지앙겐시스(Sphingomonas xinjiangensis), 스핑고모나스 야부우키애(Sphingomonas yabuuchiae), 스핑고모나스 야노이쿠이애(Sphingomonas yanoikuyae) 및 스핑고모나스 유나넨시스(Sphingomonas yunnanensis).In the present invention, microorganisms of the genus Sphingomonas include, but are not limited to, the following species: Sphingomonas abaci , Sphingomonas adhaesiva , Sphingomonas aerolata , Sphingomonas aestuarii, Sphingomonas alaskensis , Sphingomonas alpine , Sphingomonas aquatilis, Sphingomonas aromaticivorans , Sphingomonas asaccharolytica , Sphingomonas astaxanthinifaciens Sphingomonas astaxanthinifaciens , Sphingomonas aurantiaca, Sphingomonas azotifigens, Sphingomonas capsulate, Sphingomonas changbaiensis , Sphingomonas chlorophenolica , Sphingomonas chungbukensis , Sphingomonas cloacae , Sphingomonas cynarae , Sphingomonas desiccabilis , Sphingomonas dokdonensis , Sphingomonas echinoides , Sphingomonas endophytica, Sphingomonas faeni , Sphingomonas fennica , Sphingomonas formosensis, Sphingomonas ginsengisoli , Sphingomonas ginsenosidimutans , Sphingomonas glacialis , Sphingomonas haloaromaticamans , Sphingomonas hankookensis , Sphingomonas Sphingomonas herbicidovorans , Sphingomonas histidinilytica , Sphingomonas indica, Sphingomonas insulae , Sphingomonas japonica, Sphingomonas jaspsi , Sphingomonas jejuensis, Sphingomonas jinjuensis , Sphingomonas kaistensis , Sphingomonas koreensis , Sphingomonas laterariae , Sphingomonas leidyi , Sphingomonas macrogolitabida, Sphingomonas macrogoltabidus , Sphingomonas mali, Sphingomonas melonis, Sphingomonas molluscorum , Sphingomonas mucosissima , Sphingomonas natatoria , Sphingomonas olei , Sphingomonas oligophenolica , Sphingomonas oryziterrae , Sphingomonas panni , Sphingomonas parapaucimobilis, Sphingomonas paucimobilis , Sphingomonas phyllosphaerae , Sphingomonas pituitosa , Sphingomonas polyaromaticivorans , Sphingomonas pruni , Sphingomonas pseudosanguinis , Sphingomonas rosa , Sphingomonas roseiflava , Sphingomonas rubra rubra ), Sphingomonas sanguinis , Sphingomonas sanxanigenens , Sphingomonas sediminicola , Sphingomonas soli , Sphingomonas starnbergensis , Sphingomonas stygia , Sphingomonas subarctica , Sphingomonas suberifaciens , Sphingomonas subterranean , Sphingomonas taejonensis , Sphingomonas terae Sphingomonas terrae ), Sphingomonas trueperi , Sphingomonas ursincola , Sphingomonas wittichii , Sphingomonas xenophaga , Sphingomonas xinjiangensis , Sphingomonas yabuuchiae , Sphingomonas yanoikuyae , and Sphingomonas yunnanensis .

일 구체예에 있어서, 스핑고모나스 속 미생물은 스핑고모나스 올레이 일 수 있으며, 구체적으로 수탁번호 KACC 81169BP, KACC 81320BP 또는 KACC 81321BP 로 기탁된 스핑고모나스 올레이 균주일 수 있다.In one specific example, the microorganism of the genus Sphingomonas may be Sphingomonas olei, and specifically may be a Sphingomonas olei strain deposited under accession number KACC 81169BP, KACC 81320BP or KACC 81321BP.

상기 스핑고모나스 속 미생물(특히 스핑고모나스 올레이)은 1종 또는 2 이상의 종을 조합하여 사용할 수 있다. The above Sphingomonas genus microorganisms (particularly Sphingomonas olei) can be used singly or in combination of two or more species.

본 명세서에서 용어 "용해물"은 깨진 스핑고모나스 속 미생물과 같은 미생물의 세포의 수성 배지 내의 용액 또는 현탁액을 의미한다. 세포 용해물은, 예를 들어 DNA, RNA, 단백질, 펩타이드, 탄수화물, 지질 등과 같은 거대 분자 및/또는, 아미노산, 당, 지방산 등과 같은 미소분자, 또는 그의 분획을 포함한다. 또한, 상기 용해물은 매끈하거나 과립 구조일 수 있는 세포 잔해를 포함한다.The term "lysate" as used herein refers to a solution or suspension in an aqueous medium of cells of a microorganism, such as a broken microorganism of the genus Sphingomonas. A cell lysate may contain macromolecules such as DNA, RNA, proteins, peptides, carbohydrates, lipids, etc., and/or micromolecules such as amino acids, sugars, fatty acids, etc., or fractions thereof. The lysate may also contain cell debris, which may be smooth or granular in structure.

상기 미생물의 세포 용해를 달성할 수 있는 방법은 공지의 다양한 방법을 사용할 수 있으며, 미생물의 세포 용해를 달성할 수 있는 임의의 방법이 사용될 수 있다. 예를 들어 세포 개방/파괴는 효소에 의해, 화학적으로 또는 물리적으로 수행될 수 있다. 효소 및 효소 혼합물의 비제한적 예는 프로테이나아제 K와 같은 프로테아제, 리파아제 또는 글리코시다아제이고; 화학물질의 비제한적 예는 이온투과담체, 황산 도데실 나트륨과 같은 세제, 산 또는 염기이고; 물리적 수단의 비제한적 예는 프렌치 프레싱과 같은 고압, 삼투압, 열 또는 추위와 같은 온도이다. 또한, 단백질 분해 효소 이외의 효소, 산, 염기 등의 적절한 조합을 사용하는 방법 또한 사용될 수 있다. Methods for achieving cell lysis of the above microorganisms can utilize various known methods, and any method capable of achieving cell lysis of the microorganisms can be used. For example, cell opening/disruption can be performed enzymatically, chemically, or physically. Non-limiting examples of enzymes and enzyme mixtures include proteases such as proteinase K, lipases, or glycosidases; non-limiting examples of chemicals include ionophores, detergents such as sodium dodecyl sulfate, acids, or bases; and non-limiting examples of physical means include high pressure such as French pressing, osmotic pressure, and temperatures such as heat or cold. In addition, a method using an appropriate combination of enzymes, acids, bases, etc. other than proteolytic enzymes can also be used.

본 명세서에서 용어 "배양액"은 "배양 상층액", "조건 배양액" 또는 "조정 배지"와 호환적으로 사용될 수 있고, 스핑고모나스 속 미생물이 시험관 내에서 성장 및 생존할 수 있도록 영양분을 공급할 수 있는 배지에 스핑고모나스 속 미생물을 일정기간 배양하여 얻는 상기 미생물, 이의 대사물, 여분의 영양분 등을 포함하는 전체 배지를 의미할 수 있다. 또한, 상기 배양액은 미생물을 배양하여 얻은 균체 배양액에서 균체를 제거한 배양액을 의미할 수 있다. 한편, 상기 배양액 중 균체를 제거한 액체를 "상등액"이라고도 하며, 배양액을 일정시간 가만히 두어 하층에 가라앉은 부분을 제외한 상층의 액체만을 취하거나, 여과를 통해 균체를 제거하거나, 배양액을 원심분리하여 하부의 침전을 제거하고 상부의 액체만을 취하여 획득할 수 있다. 상기 "균체"는 본 발명의 미생물 자체를 의미하는 것으로 피부 샘플 등으로부터 분리하여 선별한 미생물 자체 또는 상기 미생물을 배양하여 배양액으로부터 분리한 미생물을 포함한다. 상기 균체는 배양액을 원심분리하여 하층에 가라앉은 부분을 취하여 획득할 수 있고, 또는 중력에 의해 배양액의 하층으로 가라앉으므로 일정 시간동안 가만히 두었다가 상부의 액체를 제거함으로써 획득할 수 있다.In this specification, the term "culture medium" may be used interchangeably with "culture supernatant", "conditioned culture medium" or "conditioned medium", and may mean the entire medium containing the microorganism, its metabolites, extra nutrients, etc., obtained by culturing Sphingomonas microorganisms for a certain period of time in a medium that can supply nutrients so that Sphingomonas microorganisms can grow and survive in vitro. In addition, the culture medium may mean a culture medium from which the microorganisms have been removed from a cell culture obtained by culturing the microorganisms. Meanwhile, the liquid from the culture medium from which the cell bodies have been removed is also called a "supernatant", and may be obtained by allowing the culture medium to stand still for a certain period of time and taking only the liquid in the upper layer excluding the portion that has settled to the lower layer, removing the cell bodies through filtration, or centrifuging the culture medium to remove the sediment at the bottom and taking only the liquid in the upper layer. The "cell bodies" above refers to the microorganisms themselves of the present invention, and includes the microorganisms themselves that have been separated and selected from a skin sample or the like, or the microorganisms that have been separated from the culture medium by culturing the microorganisms. The above-mentioned fungi can be obtained by centrifuging the culture solution and taking the portion that has settled to the lower layer, or by allowing the fungi to settle to the lower layer of the culture solution by gravity and then removing the upper liquid after leaving it still for a certain period of time.

일 태양에 따르면 본 발명의 스핑고모나스 속 미생물의 배양물은 미생물 배양에 사용되는 배지 중에서 통상의 기술자가 목적에 따라 용이하게 선택한 배지를 사용할 수 있다. 구체적으로 스핑고모나스 속 미생물의 배양물은, 예컨대 TSB(Tryptic soy broth) 배지, R2A (Reasoner's 2A) 배지, LB(Luria-Bertani) 배지 또는 MH(Mueller Hinton) 배지를 사용할 수 있으며, 이에 한정되지 않는다. 일 구체예에 따르면 본 발명의 스핑고모나스 속 미생물의 배양물은 상기 미생물 배양 배지에 스핑고모나스 속 미생물을 접종하고, 당업계에 공지된 미생물 배양 방법(예를 들어, 정치 배양 등)에 따라 제조할 수 있다. According to one embodiment, the culture of the Sphingomonas microorganism of the present invention can use a medium easily selected by a person skilled in the art according to the purpose among the media used for microbial culture. Specifically, the culture of the Sphingomonas microorganism can use, for example, TSB (Tryptic soy broth) medium, R2A (Reasoner's 2A) medium, LB (Luria-Bertani) medium, or MH (Mueller Hinton) medium, but is not limited thereto. According to one specific example, the culture of the Sphingomonas microorganism of the present invention can be prepared by inoculating the Sphingomonas microorganism into the microbial culture medium and using a microbial culture method known in the art (for example, static culture, etc.).

상기 배양액은 미생물을 배양하여 수득된 배양액 자체, 그의 농축물, 또는 동결건조물 또는 배양액로부터 미생물을 제거하여 수득된 배양 상층액, 그의 농축물 또는 동결건조물을 포함할 수 있다. The above culture solution may include the culture solution itself, a concentrate thereof, or a lyophilized product obtained by culturing a microorganism, or a culture supernatant obtained by removing a microorganism from the culture solution, a concentrate thereof, or a lyophilized product thereof.

상기 배양액은 스핑고모나스 속 미생물을 적절한 배지(예를 들면, TSB 배지)에서 10℃내지 40℃중 어느 온도에서 일정 시간, 예를 들면, 4 내지 50시간 동안 배양하여 수득된 것일 수 있다. 상기 스핑고모나스 속 미생물을 배양하기 위한 배양용 배지 및 배양 조건은 통상의 지식을 가진 자가 적절하게 선택하거나 변형하여 이용할 수 있다.The above culture solution may be obtained by culturing a Sphingomonas genus microorganism in an appropriate medium (e.g., TSB medium) at a temperature of 10°C to 40°C for a certain period of time, for example, 4 to 50 hours. A person of ordinary skill in the art may appropriately select or modify the culture medium and culture conditions for culturing the Sphingomonas genus microorganism.

일 구체예에서, 미생물의 배양 상층액은 미생물 배양액을 원심분리나 여과시켜 미생물을 제거하는 단계에 의해 수득될 수 있다.In one specific example, the culture supernatant of a microorganism can be obtained by a step of removing microorganisms by centrifuging or filtering the microbial culture solution.

다른 구체예에서, 농축물은 상기 미생물 배양액 자체, 또는 상기 배양액을 원심분리나 필터를 이용하여 여과한 후 수득된 상층액을 농축하는 단계에 의해 수득될 수 있다. In another specific example, the concentrate can be obtained by concentrating the microbial culture itself, or the supernatant obtained after filtering the culture using centrifugation or a filter.

본 명세서에서 용어 "추출물"은 상기 용해물, 배양액 또는 그의 농축액으로부터 추출한 것을 의미하며, 추출액, 추출액의 희석액 또는 농축액, 추출액을 건조하여 얻어지는 건조물, 또는 이들 조정제물 또는 정제물, 이를 분획한 분획물을 포함할 수 있다.The term "extract" in this specification means an extract from the above-mentioned lysate, culture medium or concentrate thereof, and may include an extract, a diluted or concentrated extract, a dried product obtained by drying the extract, or a controlled or purified product thereof, or a fraction obtained by fractionating the same.

상기 조성물은 조성물 총 중량에 대하여 0.00001 중량% 내지 80 중량%, 예를 들면, 0.00001 중량% 내지 60 중량%, 0.00001 중량% 내지 40 중량%, 0.00001 중량% 내지 30 중량%, 0.00001 중량% 내지 20 중량%, 0.00001 중량% 내지 10 중량%, 0.00001 중량% 내지 5 중량%, 0.05 중량% 내지 60 중량%, 0.05 중량% 내지 40 중량%, 0.05 중량% 내지 30 중량%, 0.05 중량% 내지 20 중량%, 0.05 중량% 내지 10 중량%, 0.05 중량% 내지 5 중량%, 0.1 중량% 내지 60 중량%, 0.1 중량% 내지 40 중량%, 0.1 중량% 내지 30 중량%, 0.1 중량% 내지 20 중량%, 0.1 중량% 내지 10 중량%, 또는 0.1 중량% 내지 5 중량%의 미생물, 또는 이의 용해물, 배양액, 또는 추출물, 또는 2종 이상 미생물의 용해물, 배양액, 또는 추출물의 혼합물을 포함할 수 있다.The composition is present in an amount of 0.00001 wt% to 80 wt%, for example, 0.00001 wt% to 60 wt%, 0.00001 wt% to 40 wt%, 0.00001 wt% to 30 wt%, 0.00001 wt% to 20 wt%, 0.00001 wt% to 10 wt%, 0.00001 wt% to 5 wt%, 0.05 wt% to 60 wt%, 0.05 wt% to 40 wt%, 0.05 wt% to 30 wt%, 0.05 wt% to 20 wt%, 0.05 wt% to 10 wt%, 0.05 wt% to 5 wt%, 0.1 wt% to 60 wt%, 0.1 wt% to 40 wt%, 0.1 It may include a microorganism, or a lysate, culture medium, or extract thereof, or a mixture of lysates, culture mediums, or extracts of two or more microorganisms, in an amount of from 0.1 wt% to 30 wt%, from 0.1 wt% to 20 wt%, from 0.1 wt% to 10 wt%, or from 0.1 wt% to 5 wt%.

본 명세서에서 용어 "유효성분으로 포함"은 상기에서 언급한 효과를 나타낼 수 있는 정도로 상기 미생물, 또는 이의 용해물, 배양액 또는 추출물이 첨가되는 것을 의미하고, 약물전달 및 안정화 등을 위하여 다양한 성분을 부성분으로 첨가하여 다양한 형태로 포뮬레이션되는 것을 포함하는 의미이다.In this specification, the term "including as an active ingredient" means that the microorganism, or its lysate, culture medium or extract is added to an extent that it can exhibit the above-mentioned effect, and includes formulating in various forms by adding various components as auxiliary components for drug delivery and stabilization, etc.

본 명세서에서 용어 "모발"은 대상체의 두피, 피부, 속눈썹, 눈썹, 콧수염 영역 및/또는 턱수염 영역의 모발을 포함한다.As used herein, the term "hair" includes hair of the scalp, skin, eyelashes, eyebrows, mustache area and/or beard area of a subject.

본 명세서에서 용어 "모발 성장 촉진"은 모발의 생성 및 성장을 촉진하여 전체 모발에서 성장기 모발의 비중을 증가시키는 것을 의미한다. 이는 새로운 모발의 생성을 촉진하는 것뿐만 아니라, 기존 모발이 건강하게 자라도록 하는 것도 포함한다. 모발 성장 촉진은 인체의 특정 영역에서 성장하는 모발 섬유의 길이를 증가시키는 것, 즉, 동일한 시간 동안 스핑고모나스 속 미생물(특히 스핑고모나스 올레이)을 사용하지 않은 모발의 길이와 비교할 때 그 기간 동안 주어진 영역의 모발의 길이를 증가시키는 것, 및/또는 모발의 밀도(즉, 피부 cm2당 모발의 수)를 증가시키는 것을 포함한다.As used herein, the term "hair growth promotion" means stimulating the production and growth of hair, thereby increasing the proportion of hair in the anagen phase among all hair types. This includes not only stimulating the production of new hair, but also promoting the healthy growth of existing hair. Hair growth promotion includes increasing the length of hair fibers growing in a specific area of the human body, i.e., increasing the length of hair in a given area over a period of time compared to the length of hair not treated with Sphingomonas spp. (particularly Sphingomonas olei ), and/or increasing hair density (i.e., the number of hairs per cm 2 of skin).

본 명세서에서 용어 "탈모(alopecia)"란 두피로부터 모발이 탈락하는 현상 또는 모발이 성기거나 가늘어지는 상태를 의미한다. 상기 탈모는 성장기 모발의 비중이 감소함에 따라 유발될 수 있다. 상기 탈모는 외인성 요인 또는 내인성 요인에 의해 유발될 수 있다. 상기 외인성 요인은 여러 가지 외부 요인, 예컨대 자외선을 말하고, 상기 내인성 요인은 시간의 흐름에 의해 발생하는 요인으로 텔로미어에 의한 모유두세포의 세포사와 세포 기능 저하에 따른 산화 스트레스 등을 포함한다. 상기 탈모는 원형 탈모증(alopecia areata), 유전성 안드로겐 탈모증 (androgenetic alopecia), 휴지기 탈모증(Telogen effluvium), 외상성 탈모증, 발모벽(trichotillomania)으로 인한 탈모, 압박성 탈모증(pressure alopecia), 생장기 탈모증, 비강성 탈모증, 매독성 탈모증(alopecia syphlltiac), 지루 탈모증(alopecia seborrhecia), 증후성 탈모증, 반흔성 탈모증, 및 선천성 탈모증 중에서 선택된 하나 이상일 수 있으나, 이에 제한되지 않는다. As used herein, the term "alopecia" refers to the phenomenon of hair falling out from the scalp or a condition in which hair becomes thicker or thinner. Hair loss can be caused by a decrease in the proportion of hair in the growth phase. Hair loss can be caused by exogenous or endogenous factors. Exogenous factors include various external factors, such as ultraviolet rays, while endogenous factors occur over time, including cell death of hair papilla cells due to telomeres and oxidative stress resulting from a decline in cell function. The above hair loss may be one or more selected from, but is not limited to, alopecia areata, androgenetic alopecia, telogen effluvium, traumatic alopecia, hair loss due to trichotillomania, pressure alopecia, anagen alopecia, pityriasis alopecia, alopecia syphlltiac, alopecia seborrhecia, symptomatic alopecia, cicatricial alopecia, and congenital alopecia.

본 명세서에서 용어 "탈모 예방"은 모발 손실을 예방, 지연 또는 방해하는 것을 의미한다. "예방"이라는 용어는 "감소"라는 용어와 상호 교환 가능할 수 있고, 이는 손실된 모발의 양을 감소시키는 것을 의미한다. 따라서, 상기 탈모 예방은 탈모 개선, 탈모 방지, 탈모 치료 등을 포함하는 의미일 수 있다.As used herein, the term "hair loss prevention" refers to preventing, delaying, or preventing hair loss. The term "prevention" may be interchangeable with the term "reduction," which refers to reducing the amount of hair lost. Therefore, "hair loss prevention" may encompass hair loss improvement, hair loss prevention, hair loss treatment, and the like.

본 발명에서 스핑고모나스 속 미생물(특히 스핑고모나스 올레이), 또는 이의 용해물, 배양액 또는 추출물은 모발 성장 촉진 또는 탈모 예방 활성을 나타낼 수 있다. 구체적으로, 스핑고모나스 속 미생물(특히 스핑고모나스 올레이), 또는 이의 용해물, 배양액 또는 추출물은 모발의 길이 성장을 촉진시키거나, 또는 모낭 세포의 성장 촉진 관련 인자, 예컨대 인슐린유사 성장인자 1(IGF-1), 혈관내피 성장인자(VEGF), 간세포 성장인자(HGF), 혈소판 유래 성장인자 소단위 A(PDGFA) 및 섬유아세포 성장인자 7(FGF7) 중 하나 이상의 발현을 증가시킬 수 있다.In the present invention, a microorganism of the genus Sphingomonas (particularly Sphingomonas olei), or a lysate, culture medium or extract thereof, may exhibit hair growth promoting or hair loss preventing activity. Specifically, a microorganism of the genus Sphingomonas (particularly Sphingomonas olei), or a lysate, culture medium or extract thereof, may promote hair length growth, or increase the expression of one or more of factors related to the promotion of hair follicle cell growth, such as insulin-like growth factor 1 (IGF-1), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), platelet-derived growth factor subunit A (PDGFA) and fibroblast growth factor 7 (FGF7).

일 구체예에서 상기 스핑고모나스 속 미생물(특히 스핑고모나스 올레이), 또는 이의 용해물, 배양액 또는 추출물은 모발 성장 촉진 또는 탈모 예방에 효과적인 다른 미생물과 함께 사용될 수 있다.In one specific example, the Sphingomonas genus microorganism (particularly Sphingomonas olei), or a lysate, culture or extract thereof, may be used together with other microorganisms effective in promoting hair growth or preventing hair loss.

본 발명의 모발 성장 촉진 또는 탈모 예방용 조성물은 모발 성장 촉진 또는 탈모 예방이 요구되는 다양한 목적 및 용도로 사용될 수 있으며, 구체적으로 화장품, 의약품(예컨대, 피부 외용제), 의약외품, 식품, 건강기능식품, 세정제, 청결제, 보존제, 방부제, 식품첨가제 또는 사료첨가제로 사용될 수 있으며, 이에 한정되지 않는다.The composition for promoting hair growth or preventing hair loss of the present invention can be used for various purposes and uses requiring promotion of hair growth or prevention of hair loss, and specifically, can be used as a cosmetic, a pharmaceutical (e.g., a topical skin preparation), an over-the-counter drug, a food, a health functional food, a detergent, a cleaning agent, a preservative, an antiseptic, a food additive, or a feed additive, but is not limited thereto.

일 구체예에서, 본 발명은 스핑고모나스 속 미생물(특히 스핑고모나스 올레이), 또는 이의 용해물, 배양액 또는 추출물을 포함하는, 모발 성장 촉진 또는 탈모 예방용 화장료 조성물일 수 있다.In one specific embodiment, the present invention may be a cosmetic composition for promoting hair growth or preventing hair loss, comprising a microorganism of the genus Sphingomonas (particularly Sphingomonas olei), or a lysate, culture solution or extract thereof.

본 발명에서, 화장료 조성물은 화장수(스킨로션), 스킨, 스킨소프너, 스킨토너, 아스트린젠트, 로션, 밀크로션, 모이스쳐 로션, 영양 로션, 마사지크림, 영양 크림, 모이스쳐 크림, 핸드크림, 손세정제, 파운데이션, 에센스, 영양 에센스, 팩, 비누, 클렌징폼, 클렌징로션, 클렌징크림, 바디로션, 바디클렌저, 현탁액, 겔, 분말, 페이스트, 마스크팩, 및 시트를 포함하는 제형으로 제조될 수 있다. 이러한 제형의 조성물은 당해 분야에서 통상적인 방법에 따라 제조될 수 있다. 상기 보습제 등의 추가 성분의 배합량은 본 발명의 목적 및 효과를 손상시키지 않는 범위 내에서 통상의 기술자가 용이하게 선정 가능하다.In the present invention, the cosmetic composition can be manufactured in a formulation including a toner (skin lotion), skin, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nourishing lotion, massage cream, nourishing cream, moisture cream, hand cream, hand sanitizer, foundation, essence, nourishing essence, pack, soap, cleansing foam, cleansing lotion, cleansing cream, body lotion, body cleanser, suspension, gel, powder, paste, mask pack, and sheet. The composition in such a formulation can be manufactured according to a method conventional in the art. The blending amount of additional ingredients such as the moisturizer can be easily selected by a person skilled in the art within a range that does not impair the purpose and effect of the present invention.

상기 화장료 조성물에는 본 명세서에 개시된 유효성분 이외에 기능성 첨가물 및 일반적인 화장료 조성물에 포함되는 성분이 추가로 포함될 수 있으며, 통상적으로 사용되는 정제수, 점증제, 방부제, 안정화제, 용해화제, 계면활성제, 담체, 향료 또는 이들의 조합을 더 포함할 수 있다. 상기 기능성 첨가물로는 수용성 비타민, 유용성 비타민, 고분자 펩티드, 고분자 다당, 스핑고 지질 및 해초 엑기스로 이루어진 군에서 선택된 성분을 포함할 수 있다. 상기 담체로서는 알코올, 오일, 계면활성제, 지방산, 실리콘 오일, 습윤제, 보습제, 점성 변형제, 유제, 안정제, 자외선산란제, 자외선흡수제, 발색제, 향료 등이 예시될 수 있다. 상기 알코올, 오일, 계면활성제, 지방산, 실리콘 오일, 습윤제, 보습제, 점성 변형제, 유제, 안정제, 자외선산란제, 자외선흡수제, 발색제, 향료로 사용될 수 있는 화합물/조성물 등은 이미 당업계에 공지되어 있기 때문에 당업자라면 적절한 해당 물질/조성물을 선택하여 사용할 수 있다. 또한, 상기 화장료 조성물에는 필요에 따라 자외선 차단제, 산화 방지제(부틸히드록시아니솔, 갈릭산프로필, 엘리소르빈산, 토코페릴아세테이드, 부틸레이티드하이드록시톨루엔 등), 방부제(메칠파라벤, 부틸파라벤, 프로필파라벤, 페녹시에탄올, 이미다졸리디닐우레아, 클로르페네신 등), 착색제, pH 조절제(트리에탄올아민, 씨트릭애씨드, 시트르산, 시트르산나트륨, 말산, 말산나트륨, 프말산, 프말산나트륨, 숙신산, 숙신산나트륨, 수산화나트륨, 인산일수소나트륨 등), 보습제(글리세린, 솔비톨, 프로필렌 글라이콜, 부틸렌 글라이콜, 헥실렌 글라이콜, 디글리세린, 베타인, 글리세레스-26, 메칠글루세스-20 등), 윤활제 등의 성분을 더 첨가할 수 있다.In addition to the effective ingredients disclosed herein, the above cosmetic composition may further include functional additives and components included in general cosmetic compositions, and may further include purified water, thickeners, preservatives, stabilizers, solubilizers, surfactants, carriers, fragrances, or combinations thereof that are commonly used. The functional additives may include components selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, high molecular peptides, high molecular polysaccharides, sphingolipids, and seaweed extracts. The carriers may include, for example, alcohols, oils, surfactants, fatty acids, silicone oils, humectants, moisturizers, viscosity modifiers, emulsifiers, stabilizers, ultraviolet scatterers, ultraviolet absorbers, colorants, fragrances, and the like. Compounds/compositions that can be used as the above alcohols, oils, surfactants, fatty acids, silicone oils, humectants, moisturizers, viscosity modifiers, emulsifiers, stabilizers, ultraviolet scatterers, ultraviolet absorbers, colorants, fragrances, etc. are already known in the art, so a person skilled in the art can select and use the appropriate corresponding substances/compositions. In addition, the cosmetic composition may further contain, as necessary, ingredients such as sunscreens, antioxidants (butylated hydroxyanisole, propyl gallate, ellisorbic acid, tocopheryl acetate, butylated hydroxytoluene, etc.), preservatives (methylparaben, butylparaben, propylparaben, phenoxyethanol, imidazolidinyl urea, chlorphenesin, etc.), colorants, pH adjusters (triethanolamine, citric acid, citric acid, sodium citrate, malic acid, sodium malate, formaldehyde, sodium formaldehyde, succinic acid, sodium succinate, sodium hydroxide, sodium hydrogen phosphate, etc.), moisturizers (glycerin, sorbitol, propylene glycol, butylene glycol, hexylene glycol, diglycerin, betaine, glycereth-26, methylgluceth-20, etc.), and lubricants.

또한, 각 제형의 화장료 조성물에 있어서 화장료의 제형 또는 사용 목적에 따라 적절한 성분들을 선정하여 배합할 수 있다. 배합 성분 및 방법은 통상의 기술에 따를 수 있으므로 그 구체적인 설명은 본 명세서에서 생략한다.Additionally, for each type of cosmetic composition, appropriate ingredients can be selected and blended according to the cosmetic formulation or intended use. Since the blending ingredients and method can be achieved using conventional techniques, a detailed description thereof is omitted herein.

본 발명의 또 다른 구체예에서, 스핑고모나스 속 미생물(특히 스핑고모나스 올레이), 또는 이의 용해물, 배양액 또는 추출물을 포함하는, 모발 성장 촉진 또는 탈모 예방용 약학 조성물일 수 있다.In another specific embodiment of the present invention, there may be provided a pharmaceutical composition for promoting hair growth or preventing hair loss, comprising a microorganism of the genus Sphingomonas (particularly Sphingomonas olei), or a lysate, culture solution or extract thereof.

본 명세서에서 용어 "약학 조성물"은, 대상체로의 투여 시에 몇몇 유리한 효과를 부여하는 분자 또는 화합물을 지칭할 수 있다. 유리한 효과는 진단적 결정을 가능하게 하는 것; 질병, 증상, 장애 또는 병태의 개선; 질병, 증상, 장애 또는 질환의 발병의 감소 또는 예방; 및 일반적으로 질병, 증상, 장애 또는 병태의 대응을 포함할 수 있다.The term "pharmaceutical composition" as used herein may refer to a molecule or compound that, when administered to a subject, imparts several beneficial effects. Beneficial effects may include enabling diagnostic determination; improving a disease, symptom, disorder, or condition; reducing or preventing the onset of a disease, symptom, disorder, or condition; and generally combating a disease, symptom, disorder, or condition.

본 명세서에서 용어 "예방"은 질환, 장애, 또는 그의 부수적 증상의 발병 또는 재발을 부분적으로 또는 완전히 지연시키거나 방지하거나, 질환 또는 장애의 획득 또는 재획득을 막거나, 질환 또는 장애의 획득의 위험을 감소시키는 방법을 말한다. 예를 들어, 상기 예방은 본 발명에 따른 조성물의 투여로 피부 손상, 또는 증상의 발생을 억제 또는 지연시키는 모든 행위를 말한다.As used herein, the term "prevention" refers to a method of partially or completely delaying or preventing the onset or recurrence of a disease, disorder, or its associated symptoms, preventing the acquisition or reacquisition of a disease or disorder, or reducing the risk of acquiring a disease or disorder. For example, the term "prevention" refers to any action that inhibits or delays the onset of skin damage or symptoms by administering a composition according to the present invention.

본 명세서에서 용어 "치료"는 질병의 발전의 억제, 경감 또는 제거를 포함한다.The term “treatment” as used herein includes inhibition, alleviation or elimination of the development of a disease.

본 명세서에서 용어 "개선"이란 상태의 완화 도는 치료와 관련된 파라미터, 예를 들면 증상의 정도를 적어도 감소시키는 모든 행위를 의미할 수 있다.The term "improvement" herein may mean any action that at least reduces the severity of a symptom, for example, a parameter related to alleviation or treatment of a condition.

본 발명에 따른 약학 조성물에서 스핑고모나스 속 미생물(특히 스핑고모나스 올레이), 또는 이의 용해물, 배양액 또는 추출물은 모발 성장 촉진 또는 탈모 예방 활성을 갖는 약학 조성물을 포함되거나, 의약 용도를 갖는 유효 성분의 보조제로서 사용할 수 있다. 상기 약학 조성물은 당해 기술분야의 통상의 기술자가 잘 알고 있는 방법에 따라 제조할 수 있다.In the pharmaceutical composition according to the present invention, a microorganism of the genus Sphingomonas (particularly Sphingomonas olei), or a lysate, culture medium or extract thereof, may be included in a pharmaceutical composition having hair growth promotion or hair loss prevention activity, or may be used as an adjuvant of an active ingredient having a medicinal use. The pharmaceutical composition may be prepared according to a method well known to those skilled in the art.

상기 약학 조성물은 목적하는 방법에 따라 경구 투여하거나 비경구로 투여가 가능하며 일반적인 의약품 제제의 형태로 사용될 수 있다. 비경구 투여는 직장, 정맥, 복막, 근육, 동맥, 경피, 비강, 흡입, 안구 및 피하와 같은 경구 이외의 투여경로를 통한 투여를 의미할 수 있다. 일 구체예에서, 상기 약학 조성물은 두피에 도포하여 사용될 수 있다.The pharmaceutical composition described above can be administered orally or parenterally, depending on the intended method, and can be used in the form of a general pharmaceutical formulation. Parenteral administration can refer to administration via routes other than oral administration, such as rectal, intravenous, peritoneal, intramuscular, arterial, transdermal, nasal, inhalational, ocular, and subcutaneous. In one specific example, the pharmaceutical composition can be applied to the scalp.

본 발명의 상기 약학 조성물을 의약품으로 사용하는 경우, 추가로 동일 또는 유사한 기능을 나타내는 유효성분을 1종 이상 함유할 수 있다.When the pharmaceutical composition of the present invention is used as a medicine, it may additionally contain one or more active ingredients exhibiting the same or similar function.

상기 약학 조성물은, 추가로 약학적으로 허용 가능한 담체를 1종 이상 포함하여 제조할 수 있다. 약학적으로 허용 가능한 담체는 식염수, 멸균수, 링거액, 완충 식염수, 덱스트로오스 용액, 말토덱스트린 용액, 글리세롤, 에탄올 및 이들 성분 중 1 성분 이상을 혼합하여 사용할 수 있으며, 필요에 따라 항산화제, 완충액, 정균제 등 다른 통상의 첨가제를 첨가할 수 있다. 또한, 희석제, 분산제, 계면활성제, 결합제 및 윤활제를 부가적으로 첨가하여 수용액, 현탁액, 유탁액 등과 같은 주사용 제형, 환약, 캡슐, 과립 또는 정제로 제제화할 수 있다. 더 나아가 당 분야의 적정한 방법으로, 각 질환에 따라 또는 성분에 따라 바람직하게 제제화할 수 있다.The above pharmaceutical composition may be further manufactured by including at least one pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers include saline solution, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, and mixtures of at least one of these components. If necessary, other conventional additives such as antioxidants, buffers, and bacteriostatic agents may be added. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate the composition into injectable formulations such as aqueous solutions, suspensions, and emulsions, pills, capsules, granules, or tablets. Furthermore, the composition may be preferably formulated according to each disease or component using an appropriate method in the art.

상기 약학 조성물을 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 비경구투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제가 포함된다. 비수성용제, 현탁용제로는 프로필렌글리콜, 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(Witepsol), 마크로골, 트윈(Tween) 61, 카카오지, 리우린지, 글리세로제라틴 등이 사용될 수 있다. When formulating the above pharmaceutical composition, it is prepared using diluents or excipients such as fillers, bulking agents, binders, wetting agents, disintegrating agents, and surfactants that are commonly used. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. Suppository bases may include Witepsol, macrogol, Tween 61, cacao butter, liurin butter, and glycerogelatin.

상기 약학 조성물은 안정성이나 흡수성을 증가시키기 위하여 글루코스, 수크로스 또는 덱스트란과 같은 탄수화물, 아스코르브산(Ascorbic acid) 또는 글루타치온과 같은 항산화제, 킬레이트화제, 저분자 단백질 또는 다른 안정화제(Stabilizers)들이 약제로 사용될 수 있다.The pharmaceutical composition may contain carbohydrates such as glucose, sucrose or dextran, antioxidants such as ascorbic acid or glutathione, chelating agents, low-molecular-weight proteins or other stabilizers to increase stability or absorbability.

본 발명의 또 다른 구체예에서, 상기 약학 조성물은 모발 성장 촉진 또는 탈모 예방용 피부 외용제 조성물일 수 있다.In another specific embodiment of the present invention, the pharmaceutical composition may be a skin external application composition for promoting hair growth or preventing hair loss.

상기 피부 외용제는 크림, 겔, 연고, 피부 유화제, 피부 현탁액, 경피전달성 패치제, 로션, 또는 그 조합일 수 있다. 상기 피부 외용제는 통상 화장품이나 의약품 등의 피부외용제에 사용되는 성분, 예를 들면 수성성분, 유성성분, 분말성분, 알코올류, 보습제, 증점제, 자외선흡수제, 미백제, 방부제, 산화방지제, 계면활성제, 향료, 색제, 각종 피부 영양제, 또는 이들의 조합과 필요에 따라서 적절하게 배합될 수 있다. 상기 피부 외용제는, 에데트산이나트륨, 에데트산삼나트륨, 시트르산나트륨, 폴리인산나트륨, 메타인산나트륨, 글루콘산 등의 금속봉쇄제, 카페인, 탄닌, 벨라파밀, 감초추출물, 글라블리딘, 각종생약, 아세트산토코페롤, 글리틸리틴산, 트라넥삼산 및 그 유도체 또는 그 염등의 약제, 비타민 C, 아스코르브산인산마그네슘, 아스코르브산글루코시드, 알부틴, 코지산, 글루코스, 프룩토스, 트레할로스 등의 당류등도 적절하게 배합할 수 있다.The above-mentioned skin external preparation may be a cream, gel, ointment, skin emulsifier, skin suspension, transdermal patch, lotion, or a combination thereof. The above-mentioned skin external preparation may be appropriately mixed with ingredients commonly used in skin external preparations such as cosmetics or medicines, such as aqueous ingredients, oily ingredients, powder ingredients, alcohols, moisturizers, thickeners, UV absorbers, whitening agents, preservatives, antioxidants, surfactants, fragrances, colorants, various skin nutrients, or a combination thereof, as needed. The above skin external preparation may also appropriately contain metal sequestrants such as sodium edetate, trisodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate, and gluconic acid; caffeine, tannin, bellapamil, licorice extract, glabridin, various herbal medicines, tocopherol acetate, glycyrrhizic acid, tranexamic acid and derivatives or salts thereof; and sugars such as vitamin C, magnesium ascorbic acid phosphate, ascorbic acid glucoside, arbutin, kojic acid, glucose, fructose, and trehalose.

본 발명에 의한 피부 외용제 조성물은 조성물 총 중량에 대하여 0.00001 중량% 내지 80 중량%의 미생물, 이의 용해물, 배양액 또는 추출물을 포함할 수 있다.The skin external application composition according to the present invention may contain 0.00001 wt% to 80 wt% of a microorganism, its lysate, culture solution or extract based on the total weight of the composition.

상기 피부는 얼굴, 손, 팔, 다리, 발, 가슴, 배, 등, 엉덩이, 및 두피를 포함하는 신체의 모든 피부 부위를 포함한다.The above skin includes all skin areas of the body, including the face, hands, arms, legs, feet, chest, stomach, back, buttocks, and scalp.

본 발명의 다른 양상은 스핑고모나스 속 미생물(특히 스핑고모나스 올레이), 또는 이의 용해물, 배양액 또는 추출물을 개체에 투여하거나 적용하는 단계를 포함하는 개체의 상태를 예방, 개선, 또는 치료하는 방법을 제공한다. Another aspect of the present invention provides a method for preventing, improving, or treating a condition of a subject, comprising administering or applying to the subject a microorganism of the genus Sphingomonas (particularly Sphingomonas olei), or a lysate, culture, or extract thereof.

상기 개체의 상태는 모발 성장 촉진 또는 탈모 예방을 필요로 하는 상태일 수 있다.The condition of the above object may be a condition requiring promotion of hair growth or prevention of hair loss.

본 명세서에서 용어 "투여하는", "적용하는", "도입하는", 및 "이식하는"은 상호교환적으로 사용되고 일 구체예에 따른 조성물의 원하는 부위로의 적어도 부분적 국소화를 초래하는 방법 또는 경로에 의한 개체 내로의 일 구체예에 따른 조성물의 배치를 의미할 수 있다.The terms "administering," "applying," "introducing," and "implanting" are used interchangeably herein and may refer to placement of a composition according to one embodiment into a subject by a method or route that results in at least partial localization of the composition to a desired site according to one embodiment.

투여는 당업계에 알려진 방법에 의하여 투여될 수 있다. 투여는 예를 들면, 정맥내, 근육내, 경구, 경피, 점막, 코안, 기관내 또는 피하 투여와 같은 경로로, 임의의 수단에 의하여 개체로 직접적으로 투여될 수 있다. 상기 투여는 전신적으로 또는 국부적으로 투여될 수 있다.Administration can be administered by any method known in the art. Administration can be administered directly to the subject by any means, including intravenous, intramuscular, oral, transdermal, mucosal, nasal, intratracheal, or subcutaneous administration. Administration can be systemic or local.

상기 개체는 포유동물, 예를 들면, 사람, 소, 말, 돼지, 개, 양, 염소, 또는 고양이일 수 있다. 상기 개체는 모발 성장 촉진 또는 탈모 예방을 필요로 하는 개체일 수 있다.The subject may be a mammal, such as a human, cow, horse, pig, dog, sheep, goat, or cat. The subject may be an individual in need of hair growth promotion or hair loss prevention.

상기 투여는 일 구체예에 따른 조성물을 개체당 일당 0.00001 mg 내지 1,000 mg, 예를 들면, 0.00001 mg 내지 500 mg, 0.00001 mg 내지 100 mg, 0.00001 mg 내지 50 mg, 0.00001 mg 내지 25 mg, 1 mg 내지 1,000 mg, 1 mg 내지 500 mg, 1 mg 내지 100 mg, 1 mg 내지 50 mg, 1 mg 내지 25 mg, 5mg 내지 1,000 mg, 5 mg 내지 500 mg, 5 mg 내지 100 mg, 5 mg 내지 50 mg, 5 mg 내지 25 mg, 10mg 내지 1,000 mg, 10 mg 내지 500 mg, 10 mg 내지 100 mg, 10 mg 내지 50 mg, 또는 10 mg 내지 25 mg을 투여하는 것일 수 있다. 다만, 투여량은 제제화 방법, 투여 방식, 환자의 연령, 체중, 성별, 병적 상태, 음식, 투여 시간, 투여 경로, 배설 속도 및 반응 감응성과 같은 요인들에 의해 다양하게 처방될 수 있고, 당해 기술분야의 통상의 기술자라면 이러한 요인들을 고려하여 투여량을 적절히 조절할 수 있다. 투여 횟수는 1일 1회 또는 임상적으로 용인 가능한 부작용의 범위 내에서 2회 이상이 가능하고, 투여 부위에 대해서도 1개소 또는 2개소 이상에 투여할 수 있으며, 매일 또는 2 내지 5일 간격으로 총 투여 일수는 한번 치료 시 1일에서 30일까지 투여될 수 있다. 필요한 경우, 적정 시기 이후에 동일한 치료를 반복할 수 있다. 인간 이외의 동물에 대해서도, kg당 인간과 동일한 투여량으로 하거나, 또는 예를 들면 목적의 동물과 인간과의 기관(심장 등)의 용적비(예를 들면, 평균값) 등으로 상기의 투여량을 환산한 양을 투여할 수 있다.The above administration is 0.00001 mg to 1,000 mg of the composition according to one specific example per subject per day, for example, 0.00001 mg to 500 mg, 0.00001 mg to 100 mg, 0.00001 mg to 50 mg, 0.00001 mg to 25 mg, 1 mg to 1,000 mg, 1 mg to 500 mg, 1 mg to 100 mg, 1 mg to 50 mg, 1 mg to 25 mg, 5 mg to 1,000 mg, 5 mg to 500 mg, 5 mg to 100 mg, 5 mg to 50 mg, 5 mg to 25 mg, 10 mg to 1,000 mg, 10 mg to 500 mg, 10 mg to 100 mg, 10 mg to 50 mg, Or it may be administered 10 mg to 25 mg. However, the dosage may be prescribed in various ways depending on factors such as the formulation method, administration method, patient's age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and response sensitivity, and a person of ordinary skill in the art can appropriately adjust the dosage by considering these factors. The frequency of administration may be once a day or twice or more within the range of clinically acceptable side effects, and the administration site may be administered in one or more sites, and the total number of administration days may be from 1 to 30 days per treatment, daily or at intervals of 2 to 5 days. If necessary, the same treatment may be repeated after an appropriate period. For animals other than humans, the same dosage as for humans per kg may be administered, or the above dosage may be converted into an amount based on the volume ratio (e.g., average value) of the organs (heart, etc.) of the target animal and humans.

또한, 본 발명은 모발 성장 촉진 또는 탈모 예방에 사용하기 위한 스핑고모나스 속 미생물(특히 스핑고모나스 올레이), 또는 이의 용해물, 배양액 또는 추출물을 포함하는 조성물을 제공한다.In addition, the present invention provides a composition comprising a microorganism of the genus Sphingomonas (particularly Sphingomonas olei), or a lysate, culture solution or extract thereof, for use in promoting hair growth or preventing hair loss.

본 발명의 또 다른 양상은 스핑고모나스 속 미생물(특히 스핑고모나스 올레이), 또는 이의 용해물, 배양액 또는 추출물로 개체를 처리하는 단계를 포함하는, 모발 성장을 촉진하거나 또는 탈모를 예방하는 방법을 제공한다.Another aspect of the present invention provides a method for promoting hair growth or preventing hair loss, comprising the step of treating an organism with a microorganism of the genus Sphingomonas (particularly Sphingomonas olei), or a lysate, culture solution or extract thereof.

이때, 스핑고모나스 속 미생물(특히 스핑고모나스 올레이), 또는 이의 용해물, 배양액 및 추출물, 그리고 모발 성장 촉진 또는 탈모 예방 활성에 대한 설명은 전술한 바와 같다.At this time, the description of the microorganisms of the genus Sphingomonas (particularly Sphingomonas olei), or their lysates, culture solutions and extracts, and their hair growth promoting or hair loss preventing activities are as described above.

스핑고모나스 속 미생물(특히 스핑고모나스 올레이), 또는 이의 용해물, 배양액 또는 추출물로 개체를 처리하는 방법은 모발 성장 촉진 또는 탈모 예방이 필요한 다양한 분야에서 통상의 기술자에게 잘 알려진 통상적인 방법에 따라 적절하게 사용될 수 있다. 스핑고모나스 속 미생물(특히 스핑고모나스 올레이), 또는 이의 용해물, 배양액 또는 추출물의 처리 양은 사용목적에 따라 적합하게 결정될 수 있다.A method for treating an organism with a microorganism of the genus Sphingomonas (particularly Sphingomonas olei) or a lysate, culture medium or extract thereof can be appropriately used according to a conventional method well known to those skilled in the art in various fields requiring promotion of hair growth or prevention of hair loss. The amount of the microorganism of the genus Sphingomonas (particularly Sphingomonas olei) or a lysate, culture medium or extract thereof can be appropriately determined depending on the intended use.

본 발명의 다른 구체예에서, 스핑고모나스 속 미생물(특히 스핑고모나스 올레이), 또는 이의 용해물, 배양액 또는 추출물을 포함하는, 모발 성장 촉진 또는 탈모 예방용 조성물은 의약외품 조성물일 수 있다.In another specific embodiment of the present invention, a composition for promoting hair growth or preventing hair loss, comprising a microorganism of the genus Sphingomonas (particularly Sphingomonas olei), or a lysate, culture solution or extract thereof, may be a quasi-drug composition.

본 명세서에서 용어 "의약외품"은 사람이나 동물의 질병을 진단, 치료, 개선, 경감, 처치 또는 예방할 목적으로 사용되는 물품들 중 의약품보다 작용이 경미한 물품들을 의미하는 것으로, 예를 들어 약사법에 따르면 의약외품이란 의약품의 용도로 사용되는 물품을 제외한 것으로, 사람ㆍ동물의 질병 치료나 예방에 쓰이는 섬유ㆍ고무 제품, 인체에 대한 작용이 경미하거나 직접 작용하지 않으며, 기구 또는 기계가 아닌 것과 이와 유사한 것, 감염병을 막기 위한 살균ㆍ살충제 등이 이에 포함된다.In this specification, the term "quasi-drug" means a product that is used for the purpose of diagnosing, treating, improving, alleviating, managing or preventing diseases of humans or animals, and has a milder effect than a drug. For example, according to the Pharmaceutical Affairs Act, a quasi-drug is a product excluding products used for the purpose of drugs, and includes fiber and rubber products used for the treatment or prevention of diseases of humans or animals, products that have a mild or no direct effect on the human body, are not instruments or machines or similar thereto, and sterilizers and insecticides for preventing infectious diseases.

본 발명의 의약외품 조성물의 종류나 제형은 특별히 제한되지 아니하나, 붕대, 거즈, 탈지면, 반창고, 소독 청결제, 샤워폼, 가그린, 물티슈, 세제 비누, 핸드 워시, 가습기 충진제, 마스크, 또는 필터 충진제 등일 수 있다.The type or formulation of the pharmaceutical composition of the present invention is not particularly limited, but may be a bandage, gauze, cotton, adhesive bandage, disinfectant, shower foam, gargle, wet tissue, detergent soap, hand wash, humidifier filler, mask, or filter filler.

본 발명의 조성물을 모발 성장 촉진 또는 탈모 예방 용도로 의약외품에 포함시킬 경우, 상기 조성물을 그대로 포함하여 사용하거나 다른 의약외품 성분과 함께 사용할 수 있고, 통상적인 방법에 따라 적절하게 사용할 수 있다. 유효 성분의 혼합량은 사용 목적에 따라 적합하게 결정할 수 있으며, 본 발명에 의한 의약외품 조성물은 조성물 총 중량에 대하여 0.01 중량% 내지 20 중량%의 미생물, 이의 용해물, 배양액 또는 추출물을 포함할 수 있다.When the composition of the present invention is included in an over-the-counter drug for the purpose of promoting hair growth or preventing hair loss, the composition may be used as is or in combination with other over-the-counter drug ingredients, and may be used appropriately according to a conventional method. The mixing amount of the active ingredients may be appropriately determined depending on the intended use, and the over-the-counter drug composition according to the present invention may contain 0.01 wt% to 20 wt% of microorganisms, their lysates, cultures, or extracts based on the total weight of the composition.

본 발명의 또 다른 구체예에서, 스핑고모나스 속 미생물(특히 스핑고모나스 올레이), 또는 이의 용해물, 배양액 또는 추출물을 포함하는, 모발 성장 촉진 또는 탈모 예방용 조성물은 건강기능식품 조성물일 수 있다.In another specific embodiment of the present invention, a composition for promoting hair growth or preventing hair loss, comprising a microorganism of the genus Sphingomonas (particularly Sphingomonas olei), or a lysate, culture solution or extract thereof, may be a health functional food composition.

상기 건강기능식품 조성물은 스핑고모나스 속 미생물(특히 스핑고모나스 올레이) 또는 이의 용해물, 배양액 또는 추출물을 단독으로 사용하거나 다른 식품 또는 식품 성분과 함께 사용할 수 있고, 통상적인 방법에 따라 적절하게 사용할 수 있다. 유효 성분의 혼합양은 사용 목적 (예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다. 일반적으로, 식품 또는 음료의 제조시에 본 명세서의 조성물은 원료에 대하여 15 중량부 이하의 양으로 첨가될 수 있다.The above health functional food composition may be used alone or in combination with other foods or food ingredients, and may be used by conventional methods, including using microorganisms of the genus Sphingomonas (particularly Sphingomonas olei) or their lysates, culture solutions, or extracts. The amount of the active ingredients may be appropriately determined depending on the intended use (prevention, health, or therapeutic treatment). Generally, when manufacturing a food or beverage, the composition of the present specification may be added in an amount of 15 parts by weight or less relative to the raw materials.

상기 건강기능식품의 종류에는 특별한 제한은 없다. 상기 물질을 첨가할 수 있는 식품의 예로는 산제, 과립제, 정제, 캡슐제, 환제, 겔, 젤리, 현탁액, 에멀젼, 시럽제, 티백제, 침출차, 및 건강 음료로 이루어진 군으로부터 선택되는 제형 등이 있으며 통상적인 의미에서의 건강식품을 모두 포함한다. 건강기능식품의 종류 중 음료 조성물은 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. There are no specific restrictions on the types of the above health functional foods. Examples of foods to which the above substances can be added include formulations selected from the group consisting of powders, granules, tablets, capsules, pills, gels, jellies, suspensions, emulsions, syrups, tea bags, infused teas, and health drinks, and include all health foods in the conventional sense. Among the types of health functional foods, beverage compositions may contain various flavorings or natural carbohydrates as additional ingredients, just like conventional beverages.

상기 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토스, 슈크로스와 같은 디사카라이드, 및 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드, 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나, 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. 상기 건강식품 조성물은 또한 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제, 또는 그 조합을 함유할 수 있다. 상기 건강기능식품 조성물은 또한, 천연 과일쥬스, 과일쥬스 음료, 야채 음료의 제조를 위한 과육, 또는 그 조합을 함유할 수 있다.The above natural carbohydrates include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As a sweetener, a natural sweetener such as thaumatin and stevia extract, or a synthetic sweetener such as saccharin or aspartame can be used. The above health food composition may also contain a nutrient, a vitamin, an electrolyte, a flavoring agent, a coloring agent, a pectic acid and its salts, an alginic acid and its salts, an organic acid, a protective colloid thickener, a pH adjusting agent, a stabilizer, a preservative, glycerin, alcohol, a carbonating agent used in carbonated beverages, or a combination thereof. The above health functional food composition may also contain fruit pulp for the production of natural fruit juice, fruit juice beverage, or vegetable beverage, or a combination thereof.

본 발명의 또 다른 양상은 수탁번호 KACC 81320BP 또는 KACC 81321BP로 기탁된 스핑고모나스 올레이 균주를 제공한다. Another aspect of the present invention provides a Sphingomonas olei strain deposited under accession number KACC 81320BP or KACC 81321BP.

수탁번호 KACC 81320BP로 기탁된 스핑고모나스 올레이 균주는 서열번호 2의 16S rRNA를 포함하고, 수탁번호 KACC 81321BP로 기탁된 스핑고모나스 올레이 균주는 서열번호 3의 16S rRNA를 포함할 수 있다. The Sphingomonas olei strain deposited with accession number KACC 81320BP may include 16S rRNA of sequence number 2, and the Sphingomonas olei strain deposited with accession number KACC 81321BP may include 16S rRNA of sequence number 3.

상기 스핑고모나스 올레이 균주는 모발의 길이 성장을 촉진시키거나, 또는 모낭 세포의 성장 촉진 관련 인자, 예컨대 IGF-1, VEGF, HGF, PDGFA 및 FGF7 중 하나 이상의 발현을 증가시킬 수 있다. 따라서, 상기 스핑고모나스 올레이 균주는 모발 성장 촉진 또는 탈모 예방 용도로 사용할 수 있다.The above Sphingomonas olei strain can promote hair length growth or increase the expression of one or more growth-promoting factors of hair follicle cells, such as IGF-1, VEGF, HGF, PDGFA, and FGF7. Therefore, the above Sphingomonas olei strain can be used for hair growth promotion or hair loss prevention.

본 발명의 다른 양상은 상기 스핑고모나스 올레이 균주의 용해물, 배양액, 또는 추출물을 제공한다.Another aspect of the present invention provides a lysate, culture solution, or extract of the Sphingomonas olei strain.

상기 스핑고모나스 올레이 균주, 이의 용해물 및 배양액에 대한 설명은 전술한 바와 같다.The description of the above Sphingomonas olei strain, its lysate and culture medium is as described above.

상기 스핑고모나스 올레이 균주의 용해물, 배양액, 또는 추출물은 모발의 길이 성장을 촉진시키거나, 또는 모낭 세포의 성장 촉진 관련 인자, 예컨대 IGF-1, VEGF, HGF, PDGFA 및 FGF7 중 하나 이상의 발현을 증가시킬 수 있다. 따라서, 상기 스핑고모나스 올레이 균주의 용해물, 배양액, 또는 추출물은 모발 성장 촉진 또는 탈모 예방 용도로 사용할 수 있다.The lysate, culture medium, or extract of the above Sphingomonas olei strain can promote hair length growth or increase the expression of one or more growth-promoting factors of hair follicle cells, such as IGF-1, VEGF, HGF, PDGFA, and FGF7. Therefore, the lysate, culture medium, or extract of the above Sphingomonas olei strain can be used for promoting hair growth or preventing hair loss.

본 발명의 일 양상에 따른 스핑고모나스 속 미생물(특히 스핑고모나스 올레이), 또는 이의 용해물, 배양액 또는 추출물을 포함하는 조성물은 모발의 길이의 생장 속도를 증진시키고 모낭 세포의 성장 촉진 관련 인자의 발현을 증가시키므로 모발 성장 촉진 또는 탈모 예방에 유용하게 사용될 수 있다. A composition comprising a microorganism of the genus Sphingomonas (particularly Sphingomonas olei) or a lysate, culture solution or extract thereof according to one aspect of the present invention can be usefully used for promoting hair growth or preventing hair loss by increasing the growth rate of hair length and increasing the expression of growth-promoting factors of hair follicle cells.

도 1은 인체 모낭 기관배양을 이용한 스핑고모나스 올레이 배양액의 모발 성장 효과를 나타낸 것으로, 인체 모낭 조직에 스핑고모나스 올레이 배양액을 4%(v/v)로 처리하고 2일, 4일째 자라나온 모발의 길이를 측정한 결과를 나타낸 그래프이다.Figure 1 shows the hair growth effect of Sphingomonas olei culture using human hair follicle organ culture. It is a graph showing the results of measuring the length of hair grown on the 2nd and 4th days after treating human hair follicle tissue with 4% (v/v) of Sphingomonas olei culture.

도 2는 인체 모낭 기관배양을 이용한 스핑고모나스 올레이 배양액의 모발성장 효과를 나타낸 사진으로, 인체 모낭조직에 스핑고모나스 올레이 배양액을 4%(v/v)로 처리한 후 6일째의 모발 사진이다.Figure 2 is a photograph showing the hair growth effect of Sphingomonas olei culture using human hair follicle organ culture. It is a photograph of hair on the 6th day after treating human hair follicle tissue with 4% (v/v) of Sphingomonas olei culture.

도 3은 사람으로부터 분리한 모유두 세포에 스핑고모나스 올레이 배양액 0.2%, 0.4%, 또는 1%(v/v) 처리 후 세포 독성을 확인한 결과를 나타낸 것이다.Figure 3 shows the results of confirming cytotoxicity after treating human breast papilla cells with 0.2%, 0.4%, or 1% (v/v) of Sphingomonas olei culture solution.

도 4는 사람으로부터 분리한 모유두 세포에 스핑고모나스 올레이 배양액 0.4% 또는 0.8%(v/v) 처리 후 48시간 후에 모낭 성장인자 IGF-1, VEGF, HGF, PDGFA 및 FGF7의 발현 정도를 실시간 PCR로 분석한 결과를 그래프로 나타낸 것이다.Figure 4 is a graph showing the results of real-time PCR analysis of the expression levels of hair follicle growth factors IGF-1, VEGF, HGF, PDGFA, and FGF7 48 hours after treatment of 0.4% or 0.8% (v/v) of Sphingomonas olei culture solution in human hair papilla cells isolated from the human body.

도 5는 사람으로부터 분리한 모유두 세포에 스핑고모나스 올레이 균주 배양액 1% 처리 후 24시간 후에 모낭 성장인자 IGF-1 mRNA의 상대적인 발현 정도를 실시간 PCR로 분석한 결과를 나타낸 그래프이다(CON, 음성대조군(멸균 증류수); So-1, 스핑고모나스 올레이 KACC 81169BP; So-2, 스핑고모나스 올레이 KACC 81320BP; So-3, 스핑고모나스 올레이 KACC 81321BP).Figure 5 is a graph showing the results of real-time PCR analysis of the relative expression level of hair follicle growth factor IGF-1 mRNA 24 hours after treatment with 1% culture of Sphingomonas olei strain in human hair papilla cells (CON, negative control group (sterile distilled water); So-1, Sphingomonas olei KACC 81169BP; So-2, Sphingomonas olei KACC 81320BP; So-3, Sphingomonas olei KACC 81321BP).

이하, 실시예를 통하여 본 발명을 보다 상세히 설명하고자 한다. 그러나, 이들 실시예는 본 발명을 예시적으로 설명하기 위한 것으로서, 본 발명의 범위가 이들 실시예에 의해 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail through examples. However, these examples are intended to exemplify the present invention, and the scope of the present invention is not limited by these examples.

실시예 1. 스핑고모나스 올레이 배양액의 제조Example 1. Preparation of Sphingomonas olei culture solution

스핑고모나스 올레이 KACC 81169BP 균주를 TSB 배지에서 34℃에서 24시간 교반 배양하여 생장 곡선상 분열 단계(Log phase)의 최종 시점에서 균주 배양액을 채집하였다. 배양액의 경우 6,000 rpm에서 30분동안 원심분리하여 0.2 μm 필터를 이용하여 여과 멸균하여 제조하였으며, 평가 및 활성 분석에 사용시 제조 후 1일을 넘지 않게 진행하였다.Sphingomonas olei KACC 81169BP strain was cultured in TSB medium at 34°C for 24 hours with stirring, and the strain culture was collected at the final point of the division phase (Log phase) of the growth curve. The culture was centrifuged at 6,000 rpm for 30 minutes and sterilized by filtration using a 0.2 μm filter. Evaluation and activity analysis were performed no longer than 1 day after preparation.

실시예 2. 스핑고모나스 올레이 배양액에 의한 모발 성장 평가Example 2. Evaluation of hair growth using Sphingomonas olei culture solution

실시예 1에서 제조한 스핑고모나스 올레이 배양액이 모발의 성장을 촉진하는지 여부를 확인하기 위해 인체 모낭 기관을 배양하여 모발 성장을 평가하였다. To determine whether the Sphingomonas olei culture prepared in Example 1 promotes hair growth, human hair follicle organs were cultured and hair growth was evaluated.

먼저, 사람 모낭 조직으로부터 모낭을 하나씩 분리한 후 피부의 진피세포인 섬유아세포의 오염을 막기 위해 피하지방층을 최대한 제거하였다. 48-웰 플레이트의 각 웰에 2 mM L-글루타민, 10 μg/mL 인슐린, 10 ng/mL 하이드로코티존과 100 μg/mL 스트렙토마이신, 및 100 U/mL 페니실린을 포함하는 350 μL의 윌리엄스 E 배지(William's E Medium)를 넣고, 한 개의 웰에 모낭을 한 개씩 넣어서 37℃, 5% CO2 세포 배양기에서 배양하였다. 실험군 당 모낭은 8개씩 이용했으며, 배양 중 배지는 이틀 마다 상기 스핑고모나스 올레이 배양액을 넣어서 교환하였다. 스핑고모나스 올레이 배양액은 4% 농도로 처리하였고 음성 대조군은 멸균 증류수를 이용했다. 길이 측정은 스핑고모나스 올레이 배양액을 넣기 전에 각 모낭의 길이를 측정하여 이것을 기준점으로 삼았다. 이틀마다 모발의 길이를 측정하여 기준점 길이를 제한 값을 모발이 성장한 길이로 하였고, 그 결과를 도 1 및 도 2에 나타내었다.First, hair follicles were isolated one by one from human hair follicle tissue, and the subcutaneous fat layer was removed as much as possible to prevent contamination with fibroblasts, which are dermal cells of the skin. 350 μL of Williams's E Medium containing 2 mM L-glutamine, 10 μg/mL insulin, 10 ng/mL hydrocortisone, 100 μg/mL streptomycin, and 100 U/mL penicillin was added to each well of a 48-well plate, and one hair follicle was placed per well and cultured in a 37°C, 5% CO 2 cell incubator. Eight hair follicles were used per experimental group, and the culture medium was replaced every two days with the Sphingomonas olei culture solution. The Sphingomonas olei culture solution was treated at a concentration of 4%, and sterile distilled water was used for the negative control group. Length measurements were taken from each hair follicle before adding the Sphingomonas olei culture medium, using this as a reference point. Hair length was measured every two days, and the reference point length was used as the hair growth length. The results are shown in Figures 1 and 2.

도 1은 인체 모낭 조직에 스핑고모나스 올레이 배양액을 4%(v/v)로 처리하고 2일 및 4일째 자라나온 길이를 측정한 결과를 나타낸 그래프이다.Figure 1 is a graph showing the results of measuring the length grown on the 2nd and 4th days after treating human hair follicle tissue with a 4% (v/v) Sphingomonas olei culture solution.

도 1은 음성 대조군과 비교했을 때 스핑고모나스 올레이 배양액 처리군에서 모낭의 길이 성장이 2일차와 4일차에서 약 20% 더 성장한 것을 관찰하였다. 따라서, 스핑고모나스 올레이 배양액이 초기 모낭 성장에 효과가 있음을 확인하였다.Figure 1 shows that, compared to the negative control group, the length of hair follicles in the Sphingomonas olei culture treatment group grew approximately 20% more on days 2 and 4. Therefore, it was confirmed that the Sphingomonas olei culture was effective in early hair follicle growth.

도 2는 인체 모낭조직에 스핑고모나스 올레이 배양액을 4%(v/v)로 처리한 후 6일째의 모발을 촬영한 사진이다. Figure 2 is a photograph of hair taken on the 6th day after treating human hair follicle tissue with a 4% (v/v) Sphingomonas olei culture solution.

상기 도 1 및 2로부터 스핑고모나스 올레이 배양액으로 처리한 경우 모발의 성장이 촉진되어 대조군에 비해 모발이 더 길게 자랐음을 알 수 있다. From the above figures 1 and 2, it can be seen that when treated with Sphingomonas olei culture solution, hair growth was promoted and the hair grew longer compared to the control group.

실시예 3. 스핑고모나스 올레이 배양액의 세포 독성 평가Example 3. Evaluation of cytotoxicity of Sphingomonas olei culture solution

실시예 1에서 제조한 스핑고모나스 올레이 배양액이 세포에 독성을 나타낼 가능성이 있는지 여부를 확인하기 위하여 세포 독성 실험을 수행하였다.A cytotoxicity test was performed to determine whether the Sphingomonas olei culture solution prepared in Example 1 could exhibit toxicity to cells.

구체적으로, 사람 모낭의 진피유두(dermal papilla: DP) 세포를 96-웰 플레이트에 2x104 세포/웰로 분주한 후, 0.25% 소혈청(fetal bovine serum: FBS), 100 μg/mL 스트렙토마이신, 100 U/mL 페니실린을 포함한 DMEM 배지(Dubelcco's modified eagle medium)에서 37℃의 5% CO2 배양기에서 배양하였다. 동일 조건에서 24시간 배양한 뒤, 스핑고모나스 올레이 배양액을 0.2%, 0.4%, 1% (v/v) 농도로 처리하고 48시간 추가 배양하였다. 이 때 배양액 대신 멸균 증류수(distilled water: DW) 처리군을 음성 대조군으로 사용하였으며, 각 웰당 전체 부피 100 μL로 진행하였다. 이 후, 각 세포 배양 웰에 10 μL의 WST-1시약을 첨가하고 동일한 조건에서 4시간동안 추가 배양한 뒤, 450 nm에서 흡광도를 측정하였고, 그 결과를 도 3에 나타내었다. Specifically, human hair follicle dermal papilla (DP) cells were seeded in 96-well plates at 2 × 10 4 cells/well and cultured in DMEM medium (Dubelcco's modified eagle medium) containing 0.25% fetal bovine serum (FBS), 100 μg/mL streptomycin, and 100 U/mL penicillin at 37°C in a 5% CO 2 incubator. After 24 h of culture under the same conditions, Sphingomonas olei culture was treated at concentrations of 0.2%, 0.4%, and 1% (v/v) and cultured for an additional 48 h. At this time, a group treated with sterile distilled water (DW) instead of the culture medium was used as a negative control, and the total volume was 100 μL per well. After this, 10 μL of WST-1 reagent was added to each cell culture well and cultured for an additional 4 hours under the same conditions, and the absorbance was measured at 450 nm, and the results are shown in Figure 3.

도 3은 실시예 1에서 제조한 스핑고모나스 올레이 배양액 처리에 따른 사람 모유두 세포의 생존 능력을 WST-1 분석으로 평가한 결과를 나타낸 그래프이다.Figure 3 is a graph showing the results of evaluating the viability of human breast papilla cells according to treatment with the Sphingomonas olei culture solution prepared in Example 1 using the WST-1 assay.

도 3에 나타낸 바와 같이, 0.2%, 0.4%, 1% (v/v)의 스핑고모나스 올레이 배양액으로 처리한 경우 음성 대조군과 비교했을 때 세포의 성장과 독성에 영향이 거의 없었다. 이로부터, 실시예 1 제조의 스핑고모나스 올레이 배양액이 세포에 독성을 나타내지 않음을 확인할 수 있다.As shown in Fig. 3, treatment with 0.2%, 0.4%, and 1% (v/v) Sphingomonas olei culture solution had little effect on cell growth and toxicity compared to the negative control group. From this, it can be confirmed that the Sphingomonas olei culture solution prepared in Example 1 did not exhibit toxicity to cells.

실시예 4. 스핑고모나스 올레이 배양액에 의한 모낭 성장인자 발현 분석Example 4. Analysis of hair follicle growth factor expression using Sphingomonas olei culture solution.

실시예 1에서 제조한 스핑고모나스 올레이 배양액이 모낭 성장인자에 미치는 영향을 평가하기 위하여, 모낭의 진피유두(DP) 세포에서 성장 인자인 인슐린 유사 성장인자 1(IGF-1), 혈관내피 성장인자(VEGF), 간세포 성장인자(HGF), 혈소판 유래 성장인자 소단위 A(PDGFA) 및 섬유아세포 성장인자 7(FGF7)의 발현을 분석하였다. In order to evaluate the effect of the Sphingomonas olei culture solution prepared in Example 1 on hair follicle growth factors, the expression of growth factors such as insulin-like growth factor 1 (IGF-1), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), platelet-derived growth factor subunit A (PDGFA), and fibroblast growth factor 7 (FGF7) in dermal papilla (DP) cells of hair follicles was analyzed.

구체적으로, 사람 모유두세포를 6-웰 플레이트에 0.25% 소혈청, 100 μg/mL 스트렙토마이신 및 100 U/mL 페니실린을 포함한 DMEM 배지에서 37℃의 5% CO2 배양기에서 배양하였다. 세포가 플레이트 면적의 80~90% 도달했을 때 배지를 교체하고 동일 조건에서 24시간 배양한 뒤, 스핑고모나스 올레이 배양액을 0.4%와 0.8% (v/v) 농도로 처리하고 다시 48시간 추가 배양하였다. 음성 대조군으로 멸균 증류수를 사용하였다. 트리졸(Trizol)을 이용해서 RNA를 추출한 후 각각 2 μg의 RNA를 사용하여 cDNA를 합성하였다. 합성된 cDNA를 주형으로 하여 타겟 유전자에 대하여 실시간 PCR을 수행하였다. 이 때 모낭 세포 성장 인자인 IGF-1, VEGF, HGF, PDGFA 및 FGF7 유전자를 타겟 유전자로 사용하였으며, 36B4 유전자에 대한 보정을 통해 최종적으로 유전자의 발현량을 분석하였고, 그 결과를 도 4에 나타내었다.Specifically, human dermal papilla cells were cultured in DMEM medium containing 0.25% bovine serum, 100 μg/mL streptomycin, and 100 U/mL penicillin in a 6-well plate at 37°C in a 5% CO2 incubator. When the cells reached 80–90% of the plate area, the medium was replaced and cultured under the same conditions for 24 h. Then, Sphingomonas olei culture was treated at concentrations of 0.4% and 0.8% (v/v) and cultured for an additional 48 h. Sterile distilled water was used as a negative control. RNA was extracted using Trizol, and cDNA was synthesized using 2 μg of RNA each. Real-time PCR was performed for the target gene using the synthesized cDNA as a template. At this time, the hair follicle cell growth factors IGF-1, VEGF, HGF, PDGFA, and FGF7 genes were used as target genes, and the expression levels of the genes were finally analyzed through correction for the 36B4 gene, and the results are shown in Figure 4.

도 4는 사람으로부터 분리한 모유두 세포에 스핑고모나스 올레이 배양액 0.4% 또는 0.8%(v/v) 처리 후 48시간 후에 모낭 성장인자 IGF-1, VEGF, HGF, PDGFA 및 FGF7의 mRNA의 상대적인 발현 정도를 실시간 PCR로 분석한 결과를 나타낸 그래프이다.Figure 4 is a graph showing the results of real-time PCR analysis of the relative expression levels of mRNA of hair follicle growth factors IGF-1, VEGF, HGF, PDGFA, and FGF7 48 hours after treatment of 0.4% or 0.8% (v/v) of Sphingomonas olei culture solution in human hair papilla cells isolated from the human body.

도 4에 나타낸 바와 같이, 0.4% 또는 0.8% 스핑고모나스 올레이 배양액 처리 시 음성 대조군 대비 IGF-1, VEGF, HGF, PDGFA 및 FGF7의 발현이 증가하였으며, 특히 0.8% 스핑고모나스 올레이 배양액 처리 시 대조군에 비해 IGF-1, VEGF, HGF, PDGFA 및 FGF7 발현이 상당히 증가하였다. 그러므로, 스핑고모나스 올레이 배양액이 모낭 성장인자의 발현을 촉진시킴을 알 수 있다.As shown in Fig. 4, the expression of IGF-1, VEGF, HGF, PDGFA, and FGF7 increased compared to the negative control group when treated with 0.4% or 0.8% Sphingomonas olei culture solution, and in particular, the expression of IGF-1, VEGF, HGF, PDGFA, and FGF7 significantly increased compared to the control group when treated with 0.8% Sphingomonas olei culture solution. Therefore, it can be seen that Sphingomonas olei culture solution promotes the expression of hair follicle growth factors.

실시예 5. 다양한 스핑고모나스 올레이 균주 배양액에 의한 모낭 성장 인자 발현 분석Example 5. Analysis of hair follicle growth factor expression by various Sphingomonas olei strain cultures.

스핑고모나스 올레이 KACC 81169BP 균주 이외에 다른 스핑고모나스 올레이 균주도 모발 성장을 촉진하는 효과가 있는지 여부를 확인하기 위해 여러 종류의 스핑고모나스 올레이 균주에 대해 진피유두 세포의 성장기에서 가장 강하게 발현되고 세포의 증식을 유도하는 대표적 성장인자인 IGF-1의 발현을 분석하였다. In order to determine whether other Sphingomonas olei strains besides the Sphingomonas olei KACC 81169BP strain have hair growth-promoting effects, the expression of IGF-1, a representative growth factor that is most strongly expressed in the growth phase of dermal papilla cells and induces cell proliferation, was analyzed for several types of Sphingomonas olei strains.

본 실시예에서는, 상기 실시예 1 내지 4에서 사용하였던 스핑고모나스 올레이 KACC 81169BP 균주에 추가하여, 건강한 한국인의 피부로부터 분리되고 16S rRNA 서열의 분석을 통해 스핑고모나스 올레이로 동정된 2개 균주(KACC 81320BP 및 KACC 81321BP)를 사용하였다. 스핑고모나스 올레이 KACC 81169BP, KACC 81320BP 및 KACC 81321BP 균주는 각각 서열번호 1 내지 3의 16s rRNA 서열을 갖는다. In this example, in addition to the Sphingomonas olei KACC 81169BP strain used in Examples 1 to 4, two strains (KACC 81320BP and KACC 81321BP) isolated from the skin of a healthy Korean person and identified as Sphingomonas olei through analysis of 16S rRNA sequences were used. The Sphingomonas olei KACC 81169BP, KACC 81320BP, and KACC 81321BP strains have the 16S rRNA sequences of SEQ ID NOs: 1 to 3, respectively.

설명explanation 서열order 서열
번호
order
number
KACC 81169BP
16S rRNA
KACC 81169BP
16S rRNA
GAGCGCAACCCTCGCCTTTAGTTACCATCATTTAGTTGGGTACTCTAAAGGAACCGCCGGTGATAAGCCGGAGGAAGGTGGGGATGACGTCAAGTCCTCATGGCCCTTACGCGCTGGGCTACACACGTGCTACAATGGCAACTACAGTGGGCAGCAATCCCGCGAGGGTGAGCTAATCTCCAAAAGTTGTCTCAGTTCGGATTGTTCTCTGCAACTCGAGAGCATGAAGGCGGAATCGCTAGTAATCGCGGATCAGCATGCCGCGGTGAATACGTTCCCAGGCCTTGTACACACCGCCCGTCACACCATGGGAGTTGGATTCACCCGAAGGCGTCGCGCTAACCGCAAGGAGGCAGGCGACCACGGTGGGTTTAGCGACTGGGGTGAGAGCGCAACCCTCGCCTTTAGTTACCATCATTTAGTTGGGTACTCTAAAGGAACCGCCGGTGATAAGCCGGAGGAAGGTGGGGATGACGTCAAGTCCTCATGGCCCTTACGCGCTGGGCTACACACGTGCTCAATGGCAACTACAGTGGGCAGCAATCCCGCGAGGGTGAGCTAATCTCCAAAAGTTGTCTC AGTTCGGATTGTTCTCTGCAACTCGAGAGCATGAAGGCGGAATCGCTAGTAATCGCGGATCAGCATGCCGCGGTGAATACGTTCCCAGGCCTTGTACACACCGCCCGTCACACCATGGGAGTTGGATTCACCCGAAGGCGTCGCGCTAACCGCAAGGAGGCAGGCGACCACGGTGGGTTTAGCGACTGGGGGTGA 11
KACC 81320BP 16S rRNAKACC 81320BP 16S rRNA AACGAGCGCAACCCTCGCCTTTAGTTACCATCATTTAGTTGGGTACTCTAAAGGAACCGCCGGTGATAAGCCGGAGGAAGGTGGGGGATGACGTCAAGTCCTCATGGCCCTTACGCGCTGGGCTACACACGTGCTACAATGGCAACTACAGTGGGCAGCAATCCCGCGAGGGTGAGCTAATCTCCAAAAGTTGTCTCAGTTCGGATTGTTCTCTGCAACTCGAGAGCATGAAGGCGGAATCGCTAGTAATCGCGGATCAGCATGCCGCGGTGAATACGTTCCCAGGCCTTGTACACACCGCCCGTCACACCATGGGGAGTTGGATTCACCCGAAGGCGTCGCGCTAACCGCAAGGAGGCAGGCGACCACGGTGGGTTTAGCGACTGGGGTGAAAACGAGCGCAACCCTCGCCTTTAGTTACCATCATTTAGTTGGGTACTCTAAAGGAACCGCCGGTGATAAGCCGGAGGAAGGTGGGGGATGACGTCAAGTCCTCATGGCCCTTACGCGCTGGGCTACACACGTGCTACAATGGCAACTACAGTGGGCAGCAATCCCGCGAGGGTGAGCTAATCTCCAAAAGTTGTCT CAGTTCGGATTGTTCTCTGCAACTCGAGAGCATGAAGGCGGAATCGCTAGTAATCGCGGATCAGCATGCCGCGGTGAATACGTTCCCAGGCCTTGTACACACCGCCCGTCACACCATGGGGAGTTGGATTCACCCGAAGGCGTCGCGCTAACCGCAAGGAGGCAGGCGACCACGGTGGGTTTAGCGACTGGGGTGAA 22 KACC 81321BP 16S rRNAKACC 81321BP 16S rRNA AACCGCCGGTGATAAGCCGGAGGAAGGTGGGGATGACGTCAAGTCCTCATGGCCCTTACGCGCTGGGCTACACACGTGCTACAATGGCAACTACAGTGGGCAGCAATCCCGCGAGGGTGAGCTAATCTCCAAAAGTTGTCTCAGTTCGGATTGTTCTCTGCAACTCGAGAGCATGAAGGCGGAATCGCTAGTAATCGCGGATCAGCATGCCGCGGTGAATACGTTCCCAGGCCTTGTACACACCGCCCGTCACACCATGGGAGTTGGATTCACCCGAAGGCGTCGCGCTAACCGCAAGGAGGCAGGCGACCACGGTGGGTTTAGCGACTGGGGTGAAAACCGCCGGTGATAAGCCGGAGGAAGGTGGGGATGACGTCAAGTCCTCATGGCCCTTACGCGCTGGGCTACAACGTGCTACAATGGCAACTACAGTGGGCAGCAATCCCGCGAGGGTGAGCTAATCTCCAAAAGTTGTCTCAGTTCGGATTGTTCTCTGCAACTCGA GAGCATGAAGGCGGGAATCGCTAGTAATCGCGGATCAGCATGCCGCGGTGAATACGTTCCCAGGCCTTGTACACACCGCCCGTCACACCATGGGAGTTGGATTCACCCGAAGGCGTCGCGCTAACCGCAAGGAGGCAGGCGACCACGGTGGGTTTAGCGACTGGGGTGAA 33

구체적으로, 실시예 1의 방법과 동일하게 제조된 배양액을 사람 모유두세포를 6-웰 플레이트에 10% FBS(Fatal calf serum), 100 μg/mL 스트렙토마이신 및 100 U/mL 페니실린을 포함한 DMEM 배지에서 37℃의 5% CO2 배양기에서 배양하였다. 세포가 플레이트 면적의 80~90% 도달했을 때 0.25% FBS-DMEM 배지로 교체하고 동일 조건에서 24시간 배양한 뒤, 스핑고모나스 올레이 배양액을 1%(v/v) 농도로 처리하고 다시 24시간 추가 배양하였다. 음성 대조군으로 멸균 증류수를 사용하였다. 트리졸을 이용해서 RNA를 추출한 후 각각 1 μg의 총 RNA를 사용하여 cDNA를 합성하였다. 합성된 cDNA를 주형으로 하여 IGF-1 유전자에 대하여 실시간(real-time) PCR을 수행하였다. 이 때 36B4 유전자에 대한 보정을 통해 최종적으로 유전자의 발현량을 분석하였고, 그 결과를 도 5에 나타내었다.Specifically, human dermal papilla cells were cultured in a 6-well plate in DMEM medium containing 10% FBS (Fatal calf serum), 100 μg/mL streptomycin, and 100 U/mL penicillin using the same method as in Example 1 in a 5% CO2 incubator at 37°C. When the cells reached 80-90% of the plate area, the medium was replaced with 0.25% FBS-DMEM and cultured under the same conditions for 24 hours, then treated with Sphingomonas olei culture medium at a concentration of 1% (v/v) and cultured for an additional 24 hours. Sterile distilled water was used as a negative control. RNA was extracted using Trizol, and cDNA was synthesized using 1 μg of total RNA each. Real-time PCR was performed on the IGF-1 gene using the synthesized cDNA as a template. At this time, the expression level of the gene was finally analyzed through correction for the 36B4 gene, and the results are shown in Figure 5.

도 5는 사람으로부터 분리한 모유두 세포에 스핑고모나스 올레이 균주 배양액 1% 처리 후 24시간 후에 모낭 성장인자 IGF-1 mRNA의 상대적인 발현 정도를 실시간 PCR로 분석한 결과를 나타낸 그래프이다(CON, 음성대조군(멸균 증류수); So-1, 스핑고모나스 올레이 KACC 81169BP; So-2, 스핑고모나스 올레이 KACC 81320BP; So-3, 스핑고모나스 올레이 KACC 81321BP).Figure 5 is a graph showing the results of real-time PCR analysis of the relative expression level of hair follicle growth factor IGF-1 mRNA 24 hours after treatment with 1% culture of Sphingomonas olei strain in human hair papilla cells (CON, negative control group (sterile distilled water); So-1, Sphingomonas olei KACC 81169BP; So-2, Sphingomonas olei KACC 81320BP; So-3, Sphingomonas olei KACC 81321BP).

도 5에 나타낸 바와 같이, 스핑고모나스 올레이 균주 3개의 배양액 처리 군 모두가 음성 대조군 대비 IGF-1의 발현이 최소 1.5배 이상 증가하였고 통계적으로도 유의미한 결과를 나타내었다(음성 대조군 대비 *p<0.05; **p<0.005). 이러한 결과로부터 스핑고모나스 올레이 종 자체가 모낭 성장인자(예컨대, IGF-1)의 발현을 촉진시키므로, 모발 성장 촉진에 효과적임을 알 수 있다.As shown in Fig. 5, all three culture groups treated with Sphingomonas olei strains showed at least a 1.5-fold increase in IGF-1 expression compared to the negative control group, and the results were statistically significant (*p<0.05; **p<0.005 compared to the negative control group). These results indicate that Sphingomonas olei strains themselves promote the expression of hair follicle growth factors (e.g., IGF-1), and are therefore effective in promoting hair growth.

Claims (10)

스핑고모나스 올레이(Sphingomonas olei), 또는 이의 용해물(lysate), 배양액 또는 추출물을 포함하는, 모발 성장 촉진 또는 탈모 예방용 조성물.A composition for promoting hair growth or preventing hair loss, comprising Sphingomonas olei , or a lysate, culture solution or extract thereof. 청구항 1에 있어서, 스핑고모나스 올레이는 수탁번호 KACC 81169BP, KACC 81320BP 또는 KACC 81321BP로 기탁된 스핑고모나스 올레이 균주인, 조성물.A composition according to claim 1, wherein Sphingomonas olei is a Sphingomonas olei strain deposited under accession number KACC 81169BP, KACC 81320BP or KACC 81321BP. 청구항 1 또는 2에 있어서, 스핑고모나스 올레이, 또는 이의 용해물, 배양액 또는 추출물이 모발의 길이 성장을 촉진시키거나, 또는 인슐린유사 성장인자 1(IGF-1), 혈관내피 성장인자(VEGF), 간세포 성장인자(HGF), 혈소판 유래 성장인자 소단위 A(PDGFA) 및 섬유아세포 성장인자 7(FGF7) 중 하나 이상의 발현을 증가시키는, 조성물.A composition according to claim 1 or 2, wherein Sphingomonas olei, or a lysate, culture or extract thereof, promotes hair length growth or increases the expression of one or more of insulin-like growth factor 1 (IGF-1), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), platelet-derived growth factor subunit A (PDGFA) and fibroblast growth factor 7 (FGF7). 청구항 1 내지 3 중 어느 한 항에 있어서, 상기 조성물은 화장품, 의약품, 피부 외용제, 의약외품 또는 건강기능식품으로 사용되는, 조성물.A composition according to any one of claims 1 to 3, wherein the composition is used as a cosmetic, a pharmaceutical, a skin external preparation, a quasi-drug, or a health functional food. 스핑고모나스 올레이, 또는 이의 용해물, 배양액 또는 추출물을 개체에게 투여함을 포함하는, 모발 성장을 촉진하거나 또는 탈모를 예방하는 방법.A method for promoting hair growth or preventing hair loss, comprising administering to a subject Sphingomonas olei, or a lysate, culture or extract thereof. 모발 성장을 촉진하거나 또는 탈모 예방에 사용하기 위한 스핑고모나스 올레이, 또는 이의 용해물, 배양액 또는 추출물을 포함하는 조성물.A composition comprising Sphingomonas olei, or a lysate, culture or extract thereof, for use in promoting hair growth or preventing hair loss. 수탁번호 KACC 81320BP 또는 KACC 81321BP로 기탁된 스핑고모나스 올레이 균주.Sphingomonas olei strain deposited under accession number KACC 81320BP or KACC 81321BP. 청구항 7에 따른 균주의 용해물.A lysate of the strain according to claim 7. 청구항 7에 따른 균주의 배양액.A culture medium of the strain according to claim 7. 청구항 7에 따른 균주의 추출물.An extract of the strain according to claim 7.
PCT/KR2025/008527 2024-06-20 2025-06-19 Use of sphingomonas sp. microorganism for promoting hair growth Pending WO2025264020A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20240080683 2024-06-20
KR10-2024-0080683 2024-06-20

Publications (1)

Publication Number Publication Date
WO2025264020A1 true WO2025264020A1 (en) 2025-12-26

Family

ID=98213613

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2025/008527 Pending WO2025264020A1 (en) 2024-06-20 2025-06-19 Use of sphingomonas sp. microorganism for promoting hair growth

Country Status (1)

Country Link
WO (1) WO2025264020A1 (en)

Also Published As

Publication number Publication date
KR20250179685A (en) 2025-12-30

Similar Documents

Publication Publication Date Title
KR101980071B1 (en) Composition comprising Streptococcus thermophilus strain and culture medium thereof
TWI842139B (en) A composition for improving skin condition and a novel sphingomonas olei strain and a lysate, a culture solution, an extract thereof
KR20210025317A (en) A genus of Staphylococcus strain and uses thereof
WO2019143055A1 (en) Composition, comprising extract of fermented beans obtained from fermentation by aspergillus fumigatus strain, for skin care improvement
KR102495405B1 (en) Micrococcus luteus strain and its use for improving hair or scalp condition
WO2016056781A1 (en) Composition for hair loss prevention or hair growth stimulation comprising artemisia umbelliformis extract
WO2025154961A1 (en) Cosmetic composition comprising organoid culture medium
WO2025009766A1 (en) Bifidobacterium animalis subsp. lactis strain and use thereof for improving hair or scalp condition
EP4403624A1 (en) Scalp microbiome complex and use thereof for improving hair or scalp condition
WO2025264020A1 (en) Use of sphingomonas sp. microorganism for promoting hair growth
KR102909443B1 (en) Use of Sphingomonas sp. for promoting hair growth
KR102480529B1 (en) Cutibacterium granulosum strain and its use for improving hair or scalp condition
KR102361014B1 (en) Use of Dermacoccus nishinomiyaensis to improve skin condition
WO2016056780A1 (en) Composition for hair loss prevention or hair growth stimulation comprising scutellaria alpina extract
KR102467931B1 (en) Brevibacillus borstelensis strain and its use for improving hair or scalp condition
KR102480526B1 (en) Dietzia cinnamea strain and its use for improving hair or scalp condition
WO2023224274A1 (en) Cosmetic composition comprising supercritical extract of fusidium coccineum strain cells
KR102495404B1 (en) Brevundimonas vesicularis strain and its use for improving hair or scalp condition
KR102480528B1 (en) Streptococcus pneumoniae strain and its use for improving hair or scalp condition
KR102495400B1 (en) Novosphingobium humi strain and its use for improving hair or scalp condition
KR102495403B1 (en) Deinococcus wulumuqiensis strain and its use for improving hair or scalp condition
KR102411240B1 (en) Use of Phycicoccus jejuensis to improve skin condition
WO2025173928A1 (en) Composition for scalp improvement using pseudomonas and micrococcus and method for preparing same
KR102495401B1 (en) Yimella lutea strain and its use for improving hair or scalp condition
WO2023277629A1 (en) Composition comprising hydrangenol as active ingredient for improving hair or scalp condition